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Combination Therapy of oral hypoglycaemic agents ( OHA ) with insulin 
* can achieve similar glycaemic control at a lower insulin dosage and with less 
weight gain when compared to Insulin Therapy alone in Chinese NK)DM 
patients with secondary drug failure. 
The outcomes of 55 secondary drug failure subjects were evaluated at 3-
month, 6-month, and at a mean follow-up duration of 21-month ( range 18-26 ) 
in comparison between the continuation of maximum OHA plus additional 
bedtime insulin ( Combination Group n = 28 )，and full insulin therapy after 
stopping OHA ( Insulin Group n = 27 ). All patients were evaluated for body 
weight, glycaemic control, lipids, side effects and quality of life. Of the original 
55 patients, 7 were excluded from this analysis during the final evaluation ( 4 
from the Combination Group had been switched to full insulin therapy; 1 from 
the Insulin Group stopped insulin on her own, 2 defaulted and contact was lost). 
Both groups maintained good glycaemic control when compared to 
baseline. Fasting plasma glucose decreased from 13.5 土 2.7 mmoI/L to 8.4 土 3.6 
mmoUL ( P < 0.001 ); and from 13.5 土 3.6 mmoL0:^  to 9.4 土 3.8 mmoUL ( P < 
0.001 ) for Combination and Insulin Groups respectively. Similarly, both groups 
* 
had significant improvement of HbAic and fructosamine. HbAic improved from 
10.2 土 1.3o/o to 8.9 土 1.3o/o ( P < 0.001 ) in the Combination Group and from 
10.7 土 2.0o/o to 8.8 土 2.0o/o ( P < 0.001 ) in the Insulin Group. Fructosamine fell 
from 458 土 97 ^moLO. to 352 土 64 \imoUL P < 0.001 ) in the Combination 
Group and from 484 土 83 ^moLO. to 341 土 76 nmol/L P < 0.001 ) in the Insulin 
Group. All glycaemic indices were similar at 6 months and 21 months for both 
groups and there were no significant differences observed between the 2 groups. 
Despite similar glycaemic improvement, insulin dosage requirements 
continued to show a marked difference [ Combination Group 16.4 土 6.3 U/day 
vs Insulin Group 60 土 20.1 U/day ( P < 0.001 ) ]. Both groups gained weight 
progressively when compared to baseline. Combination group : 2 土 2.1 kg ( P < 
0.001 ); Insulin Group : 6 土 3.2 kg ( P < 0.001 ). Weight gain was significantly 
greater in the Insulin Group ( P < 0.02 ). No significant changes in lipid profiles 
were recorded. Despite occasional mild hypoglycaemia, well-being and quality of 
life improved significantly in both groups. 
With a much lower weight gain and insulin dose requirement, it is 
concluded that Insulin-OHA Combination Therapy for secondary drug failure 
can be an effective intermediate stage prior to full insulin replacement therapy. 
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1.1 GENERAL INTRODUCTION 
Diabetes mellitus is a heterogeneous disorder with both genetic and 
environmental factor determinants. Although the classification of diabetes 
mellitus is currently under review, according to the current World Health 
Organization classification, diabetes is divided into 2 major sub-types, insulin-
dependent (K)DM ) or type 1 and non-insulin-dependent diabetes mellitus ( 
NK)DM ) or type 2. There are now epidemics of NK)DM in developing 
countries and it is a major cause of early mortality and cardiovascular morbidity. 
(Zimmet, 1991) 
In the treatment of diabetes, the main therapeutic goal is to optimize 
metabolic control, to reduce the risk of long term complications. The beneficial 
effects of optimal glycaemic control in IDDM has been confirmed in the Diabetes 
Control and Complications Trial ( DCCT ). Patients treated intensively had 60% 
risk reduction in the development and progression of all microangiopathic 
complications, underlying retinopathy, neuropathy and nephropathy (Nathan， 
Siebert & Genuth’ 1994). A recent 6 year study from Japan (Ohkubo, 
Kishikawa, Araki, Miyata, Isami, Motoyoshi, Kojima, Furuyoshi & Shichiri, 
1995) also extended this observation to a group of young NK)DM patients 
treated with insulin. 
Approximately 85% of diabetic subjects have type II，or NK)DM. In 
Caucasians, the onset of NTODM is usually in the middle or later years of life 
2 
with the majority ofyoung patients suffering from H)DM. However, among non-
Caucasians including Chinese, NK)DM remains the predominant form of 
diabetes in patients with young onset of disease ( <30 years ) (Chan, Yeung, 
Chow & Cockram, 1996). Compared to the Caucasian populations, Type I 
diabetes or H)DM is considerably less common among non-Caucasians including 
the Chinese populations. 
NK)DM is characterized by chronic hyperglycaemia with varying degrees 
of insulin resistance and insulin deficiency. It is closely associated with ageing, 
obesity, hypertension, hyperlipidaemia and increased cardiovascular disease 
related morbidity and mortality (Lebovitz, 1994). 
Due to progressive pancreatic p cell failure, despite adequate diet, 
exercise and oral hypoglycaemic agent ( OHA ) therapy, many NLDDM patients 
fail to achieve adequate glycaemic control and maintain glycosylated 
haemoglobin (HbAic) concentrations at acceptable levels. 
n)DM is characterized by absolute insulin deficiency so that insulin 
treatment is essential in these patients to maintain survival to prevent acute 
metabolic decompensation. On the other hand, both impairment of beta cell 
insulin secretion ( p cell insufficiency ) and insulin insensitivity in muscle and 
liver ( insulin resistance ) contribute to the hyperglycaemia in NEDDM. In the 
presence of moderate to severe hyperglycaemia, both p cell insufficiency and 
3 
j • 
insulin resistance defects are usually present ODeFronzo, 1988). However their 
relative contributions vary from patient to patient. Furthermore, glucose toxicity 
may further impair insulin secretion and increase insulin resistance which interact 
with one another. In NK)DM patients who fail oral treatment, insulin treatment 
in relatively large doses are required to normalize blood glucose concentrations 
which may lead to significant weight gain (Lebovitz, 1994). In NK)DM, full 
insulin replacement can be given after withdrawal of OHA. Alternatively, insulin 
can be given as a supplementary therapy with continuation of OHA therapy ( 
Combination Therapy ). 
Combination sulphonylurea-insulin therapy has been tried as a method of 
treatment for NK)DM patients since the 1950's. Examples include the use of 
insulin-tolbutamide combination therapy in U.S.A. although the efficacy of said 
therapy has not fully evaluated (Fabrykant & Ashe，1959; Lazarus & Volk， 
1959). Recently, there has been renewed interest in the use of such combination 
therapy as an alternative to insulin monotherapy in NK)DM with secondary 
OHA failure as well as its effect on quality of life can be obtained (Bachmann, 
Lotz & Mehnert, 1988) 
The aim of this thesis is to examine the efficacy and acceptability of 
combined insulin-oral hypoglycaemic agent ( OHA ) therapy in Hong Kong 
Chinese NIDDM patients with secondary OHA failure. This therapy involved the 
4 
i t 
additional bed-time insulin to the maximum dosage of OHA and was compared 
with the full replacement insulin therapy after withdrawal of OHA. 
5 
L2 LITERA TURE REVIEW 
L2,1 Classification of Diabetes Mellitus 
According to the World Health Organization Classification (1985), the 
two major sub-types of diabetes mellitus are Type 1, Insulin-Dependent Diabetes 
Mellitus (K)DM) and Type II, Non-Insulin-Dependent Diabetes Mellitus 
QSrn3DM). The WHO classification is summarized in Table 1.1. and was based 
on the differences in etiology, natural history and clinical presentation as well as 
the dependence of an individual on insulin to prevent death from acute metabolic 
decompensation. (WHO, 1985) 
1.2.2 Diagnostic Criteria of Diabetes Mellitus 
Diabetes mellitus is a very common chronic disease which is associated 
with morbidity and early mortality. The diagnosis of diabetes should be made 
with care and should not depend solely on the presence or absence of glycosuria 
or capillary blood glucose concentrations. 
D3DM is characterized by a relatively abrupt onset, with severe 
symptoms of weight loss and ketosis and usually affects young patients. In 
U.S.A., D3DM accounts for approximately 10% of all people diagnosed to have 
DM. (ADA, 1992). However, the prevalence is much lower in Asian countries. 
6 
Table 1.1 : The WorldHealth Orsanization classification of 
diabetes mellitus and allied cateeories of 2luc0se intolerance 
L Clinical classes 
L Insulin-dependent diabetes meUUus 
(IDDMortypeI) 
2 Non-insuUn-dependent diabetes meUUus 
(NIDDMortypeII) 
type IIa = non-obese 
type II b = obese 
3. Mahiutrition reUUed diabetes mellUus 
(MRDM) 
4. Secondary and other types of diabetes 
(with associated conditions or syndromes ) 
a, pancreatic diseases 
b. disease of hormonal etiology 
(acromegaly, CusMng,ssyndrome, 
glucagonoma, pheochromocytoma ) 
a drug-induced or chemical-induced conditions 
d. abnormalities of insulin or 'Us receptors 
e. certain genetic syndromes 
f . miscellaneous 
5. Impaired ghicose tolerance 
obese 
non-obese 
6. Gestational diabetes mellitus 
//• Statistical risk classes ( subjects with normal glucose tolerance 
but substantially increased risk of developing diabetes) 
1. Previous abnormality of glucose intolerance 
2, Potential abnormality of glucose intolerance 
WHO (1985). Diabetes mellitus : Report ofa WHO Study Group. Geneva, 
WorldHealth Organization Technical Report Series, No. 727 
(This classification is currently being reviewed and revised. 
At the time ofwriting, this process has not been completed.) 
7 
(Chan et aL’ 1996) Due to the absolute insulin deficiency, insulin therapy is 
essential to maintain survival. 
The onset of NK)DM is usually more insidious and patients are often 
asymptomatic, and may result in late presentation with complications. Although 
NK)DM is a disease of ageing and usually diagnosed after the age of 40 years in 
Caucasians, it commonly occurs at an early age in non-Caucasians. 
In the presence of typical symptoms of NK)DM, i.e. thirst, polyuria, 
weight loss, a diagnostic fasting ( > 7.8 Tc\moVL ) or random blood plasma 
concentration ( > 7.8 mmoUL ) is sufficient for the diagnosis. However, in 
asymptomatic individuals, two diagnostic blood glucose values are preferred. In 
subjects with equivocal or non-diagnostic values, oral glucose tolerance test ( 
OGTT ) is recommended (Watkins, 1993). The 75 OGTT is also used as a 
diagnostic test in asymptomatic subjects suspected to have diabetes (Akinmokun, 
Harris, Home & Albeti, 1992) The diagnostic 2-hour plasma glucose 
concentration of 11.1 mmol/L correlates well with the development of 
microangiopathic complications. However, the diagnostic fasting plasma glucose 
concentration > 7.8 mmoL^ has low sensitivity and specificity. The current 
WHO diagnostic criterion is currently under review and the fasting plasma 
glucose concentration may be lowered to between 6.5 and 7 mmol/L (Cockram, 
Lau，Chan, Woo & Swaminathan, 1992). Until then, the 75g OGTT remains the 
gold standard for the diagnosis of glucose intolerance. The high risk groups who 
8 
should be screened for diabetes are listed in Table 1.2. The WHO diagnostic 
criteria for screening glucose intolerance is shown in Table 1.3. 
1.2.3 Characteristics ofNIDDM 
NK)DM is a heterogeneous disorder characterized by a non ketotic 
presentation with slow progression. NIDDM may present at any age but 
predominantly affects older subjects. Over 70% of affected subjects are aged 55 
years or above. Obesity, family history, ageing, physical inactivity and 
urbanization are the major risk factors ( Table 1.4 ). 
Certain populations and ethnic groups appear to be more prone to 
develop NK)DM than others. This can be reflected by the markedly variations in 
prevalence among different ethnic groups living in the same environment and 
among the same ethnic group living in different areas. Migrant studies have 
shown that populations that move rapidly from a rural lifestyle to a more 
sedentary type of existence are particularly at risk (King & Zimmet，1988). 
Examples include Indian Americans, Pacific Islanders, Australian Aborigines and 
migrant Asian Indians. Pima Indians in Arizona have the highest rate ofNK)DM 
in the world. By contrast, the prevalence of diabetes in Pima Indians living in 
Northern Mexico is very low. Marked variations in NH)DM prevalence rates 
have also been found in the Chinese population increasing from less than 1% 
9 
Table L2 : 
Hieh Risk Subjects Who Should Be Screened For Diabetes Mellitus 
L Positive family history 
2. History of impaired glucose tolerance 
3. Women given birth to macrosomic infants and large babies 
4. Multi-para women ( more than 3 pregnancies ) 
5. History of gestational diabetes mellitus 
6. Frequent abortions 
7. History of glucose intolerance secondary to other drugs 
8. Obesity 
« 
9. Metabolic alterations 
10 
i . 
Table 1.3 : The diasnostic criteria ofelucose intolerance usins 
75 2ram oral elucose tolerance test 
Glucose concentration, mmol/liter (ms/dl) 
Wholeblood Plasma 
Venous Capillary Venous Capillary 
Diabetes mellitus 
Fasting > 6.7 > 6.7 > 7.8 > 7.8 
(> 120) ( > 120) ( > 140) ( > 140) 
2-hour > 10.0 > 1L1 > 11.1 > 12.1 
(>180) (> 200) (>200) (>200) 
Impaired elucose tolerance 
Fasting < 6.7 < 6,7 < 7,8 < Z8 
(<120) (<120) (<140) (:140) 
2'hour 6.7-10.0 7,8-11.1 7.8-11.1 8.9-12.2 
(120-180) (140 - 200) (140-200) (160 - 220) 
N.B. ： normal carbohydrate intake and physical activity for 3 dqys 
before the test, no smoking during the test 
in cUnical settings, diagnosis shouU be made on the basis 
of 2 vdbies in asymptomatic subjects or 1 vaUie 
in the presence ofsymptoms 
tonversion factor: mmolA = mg/dl + 18. 
aU values given as mmolA 
plasma gbicse ~ wkole bU>od gUicose x 1,12 
WHO (1985). Diabetes meUUus: 
Report of a WHO Study Group. 




























































































































































































































































































































































































































































































































































amongst Chinese in rural areas of Mainland China to 6-12% amongst Chinese 
living in affluent societies such as Hong Kong, Taiwan and Singapore and to 
over 16% amongst Chinese in Mauritius ^)owse, Gareeboo, Zimmet, Alberti, 
Tuomilehto, Fareed, Brissormette, Finch & Group，1990; Bourn, 1995). The 
prevalence rates ofNK)DM in different populations are shown in Table 1.5. 
1.2.4 Evidemiolo2V Of NIDDM 
Non-insulin-dependent diabetes predominates on a global basis affecting 
over 95% of diabetic subjects. It is also the predominant form of diabetes 
amongst the non-Caucasians even in patients with young onset of disease 
(Tajima, LaPorte, Hibi, Kitagawa, Fujita & Drash, 1985). The World Health 
Organization ( WHO ) has estimated that over 100 million people have diabetes 
worldwide. Of these, 60 million are in the developing countries. Further 
projections indicate an increase to over 160 million by the year 2000 (Bourn, 
1995). 
The prevalence rate of NK)DM is approximately 5% in Europe (King & 
Zimmet, 1988). Half a million people in the United Kingdom are affected by 
NK)DM. In the United States, 13 million people have diabetes, with 10% having 
H)DM and 90% having NIDDM. Approximately 60% of newly diagnosed cases 
are women (Bennet & al, 1995). It is the sixth commonest cause of death in the 
United States. 
13 
i i , ! 
Table L5 : Prevalence ofNIDDMin Certain Different Populations 
Pnpulatinn Grnup 冊麗 WDM 
,肩"卯 Mak Emak 
Pima Indians 49% 51% 
Arizona, USA 
Nauru 41% 42% 
Micronesia 
Urban Indian 23% 20% 
» ^ « • • 
Fjui 
RuralIndian 26% 16% 
Fiii 
Hispanic Americans 18% 13% 
New York, USA 
African 9% 12% 
Americans 
American Whites 5% 7% 
Chinese 1% 1% 
Da Oins 
RuralMelanesian 0% 0% 
Papua, New Guinea 
(Bourn, 1995) 
14 
Due to increasing personal affluence and westernization, the prevalence 
ofDM in Asia is increasing at epidemic rates, it has been estimated that there are 
300,000 or more people with diabetes in Hong Kong, of whom 60% are 
undiagnosed (Cockram, Woo, Chan, Chan, Lau, Swaminathan & Donnan, 1993) 
(Janus, Cockram, Lam & Lam，1996). 
Among Chinese, who represent 20% of the global population, the 
prevalence of diabetes rises from less than 1% in some rural areas in Mainland 
China to 6-12% amongst Chinese living in modernized societies such as Hong 
Kong (Chan et al., 1996). The prevalence of diabetes in Hong Kong Chinese was 
estimated to be 4.5% in the working population (Cockram et al., 1993) and over 
10% among the elderly (Woo, Swaminathan, Cockram, Pang, Mak, Au & 
Vallance-Owen, 1987) in the late 80 and early 90s. More recent data confirm the 
rising prevalence now estimated to be 8% in the general population increasing to 
over 25% in the elderly. (Xung et al, 1996) These findings are consistent with 
the prevalence of NK)DM reported among overseas Chinese which ranges 
between 6-12% (Zimmet, 1992; King, Rewers & Group.，1993). 
In Japan, the prevalence of NK)DM ranges from 4-12% (Akazawa, 
1994). In Singapore, the prevalence has doubled from 4% to 8% over a period 
of 10 years (Thai, Yeo, Lun, Hughes, Wang, Sothy, Lui, Ng, Cheak, Phoon & 
Lim，1987) and a similar situation exists in Taiwan (Chou, Chen & Hsiao，1992). 
15 
The prevalence of diabetes is also rising rapidly in China OPan, Lu, Tian, Kong, 
Lu, Yao, Jiang, Deng, Wang, Zhang, Wang & Cui, 1996). 
L2,5 PathoDhvsiolo2V ofNIDDM 
NK)DM, a state of insulin resistance, exacerbated by relative insulin 
deficiency, is often associated with a cluster of other cardiovascular risk factors 
known as "The Metabolic Syndrome" (Reaven, 1988). Features closely 
associated with glucose intolerance include dyslipidaemia, obesity, ( general and 
central )，hypertension and atherosclerosis (Horky, 1993) ( Table 1.6 ). In 
particular, there are close associations between hypertension and NK)DM which 
explain much of the early mortality and cardiovascular morbidity in modem 
societies (DeFronzo & Ferrannini，1991; Fuller & Stevens，1992). In Hong 
Kong, the prevalence of diabetes and hypertension have been reported to be 
approximately 5-10% in the general working population (Cockram et al., 1993; 
Chan, Cheung, Lau, Woo, Swaminathan & Cockram, 1996). The prevalence of 
hypertension is 7% in the non-diabetic population as compared to 26% among 
the diabetic subjects (Woo, Lau, Chan, Cockram & Swaminathan，1992). 
1.2.6 Determinants and Causes of NIDDM 
Insulin reduces blood glucose by suppressing lipolysis and peripheral 
glucose production by gluconeogenesis and glycogenolysis. Insulin also enhances 
glucose uptake by muscle and liver for energy utilization or storage as glycogen 
16 
i • 




Increased Very Low Density Lipoprotein triglycerides 







or triglycerides. Insulin resistance is defined as reduced action of insulin at 
peripheral tissues and is a strong predictor for NIDDM. The pathogenesis for 
insulin resistance remains to be clarified. Decreased early phase insulin secretion 
in response to an oral or intravenous glucose challenge has also been 
demonstrated in subjects with NK)DM or impaired glucose tolerance (Haffner, 
Miettinen & Stem, 1996). This defect in early phase insulin secretion appears to 
be related to a reduced responsiveness of beta-cell to glucose stimulus (Cerasi, 
1991). 
Although hyperinsulinaemia and insulin resistance are strong predictors 
for ND3DM, insulin deficiency plays an important role in the development of 
overt diabetes. The relative importance of these factors (Defronzo, Bonadonna 
& Ferrannini，1992; Yki-Jarvinen, Kauppila, Kujansuu, Lahti, Marjanen, 
Niskanen, Rajala, Ryysy, Salo, Seppala, Tulokas, Viikari, Karjalainen & 
Taskinen，1992) may vary considerably between different individuals. Subjects 
with greater insulin sensitivity are able to withstand a more severe degree of 
insulin secretory failure than insulin resistant subjects before developing overt 
hyperglycaemia. Hyperglycaemia per sae (glucose toxicity) may also worsen 
insulin resistance and reduce insulin secretion and perpetuate the vicious cycle. 
This relationship is being shown in Figure 1.1. 
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Fi2ureLl : Relationshws between insulin resistance and 
insulin secretion in non-insulin-devendent diabetes mellitus 
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^ impairedfi-cell function ^ post-receptor defect 
[Moller and Flier, 1991J 
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7.2 7 Etiolo2v and Risk Factors for NIDDM 
LZ7,1 Genetic Factors 
Family studies such as monozygotic twin studies, suggest a strong 
genetic component for MDDM although the exact modes of inheritance are 
uncertain (Ramachandran, Mohan, Snehalatha & Viswanathan, 1988). Due to 
the complexity of the disease process which involves insulin resistance, insulin 
deficiency and glucose toxicity. MDDM is likely to be a polygenic disease 
triggered by other factors such as ageing and obesity (Taylor, Accili & Imai, 
1994; Yki-Jarvinen, 1994). 
1.2.7.2 Environmental Factors 
1.2,7.2,1 Physical Inactivity 
Diet and exercise remain the first line of treatment in the management of 
MDDM There are also increasing experience showing that a proper high fiber 
diet improves hyperglycaemia (Pearson & Wales, 1988; Fernandez, Gonzalez, 
Lopez-Cozar, Lobon, Aguirre & Escobar-Jimenez，1990). 
Physical inactivity and the adoption of a Westernized diet characterized 
by energy-dense foods rich in saturated fats and lack of complex carbohydrate 
foods and fibers are risk factors for glucose tolerance. There are also much 




NK)DM and related diseases. Regular physical activity increases insulin 
sensitivity and improves glucose tolerance (Zimmet, 1992). 
Apart from physical inactivity, alcohol and smoking are associated with 
increased cardiovascular risks while the nature of these associations remain to be 
clarified. It has been hypothesized that these social habits may reflect an 
underlying stress response which itself may lead to increased cardiovascular risks 
O^ewberry, Jaikins-Madden & Gerstenberger, 1991) and development of the 
Metabolic Syndrome. (Bjorntorp, 1991) 
i . 2 7.i Body Weight and Fat Distribution 
Obesity is a strong predisposing factor ofNDDDM and insulin resistance. 
Body Mass Index ( BMI) is positively associated with increased risk ofNK)DM 
in both sexes and this relationship is demonstrable in many ethnic groups. 
(Dowse, Zimmet, Gareeboo & al, 1991) (Hodge, Dowse, Zimmet & Collins， 
1995) (Seidell, 1995) Waist-hip ratio (WHR), an indicator of central obesity, 
also has important influences upon glucose tolerance, blood pressure and serum 
lipids levels.. 
Obesity and glucose intolerance represent parts of a multi-faceted 
syndrome involving hypertension, dyslipidaemia and hyperinsulinaemia 
(DeFronzo & Ferrannini, 1991). There are increasing evidence suggesting that 
intra-abdominal fat deposits may constitute greater cardiovascular risk than 
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general or lower body obesity OPeiris, Sothmann, Hoffinann, Hennes, Wilson, 
Gustafson & Kissebah，1989; Pouliot, Despres, Lemieus, Mooijani, Bouchard， 
Tremblay, Nadeau & Lupien, 1994; Richelsen & Pedersen, 1995) and are also 
strong predictors for glucose intolerance. 
Central obesity is also associated with insulin resistance, dyslipidaemia 
and glucose intolerance (Cerasi, 1991). Findings from twin studies suggest that 
there may be genetic influence in the development of central abdominal obesity 
with its associated metabolic consequences (Carey, Nguyen, Campbell, Chisholm 
&K:elly, 1996). 
1,2,7,4 Gestational Diabetes Mellitus 
Gestational Diabetes Mellitus ( GDM ) is a known risk factor for glucose 
intolerance (Csorba & Edwards, 1995). A history of gestational diabetes, 
multiparity and delivery of a macrosomic infant are associated with increased risk 
for development of both gestational diabetes in future pregnancies and 
subsequent development ofNK)DM (Csorba & Edwards，1995; McGuire, Rauh, 
Mueller & Hickock，1996). The incidence of GDM was estimated to be 3% of all 
pregnancies. ‘ Although it usually disappears after delivery (ADA, 1992)， 
hyperglycaemia during pregnancy is associated with increased foetal morbidity. 
Hence, subjects with GDM should have good glycaemic control during 
pregnancy to improve foetal outcome. 
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1.2.7.5 Impaired Glucose Tolerance (IGT) 
Although subjects with impaired Glucose Tolerance ( IGT ) are 
asymptomatic and have lower levels of hyperglycaemia than diabetic patients, a 
significant proportion of people with IGT have increased cardiovascular risk 
factors such as hypertension, decreased high-density lipoprotein levels and 
increased plasma triglycerides. Subjects with IGT also have increased risk of 
developing diabetes mellitus and atherosclerosis (Jarrett, Cartney & Keen, 1982; 
DeFronzo, 1988; Zimmet, 1992). 
Several epidemiological studies have shown that subjects with low-birth 
weight are at increased risk of developing diabetes in adulthood especially if 
obesity develop in later years. This association has been shown in Caucasian 
subjects from the United Kingdom (Hales, 1991) and in a bi-ethnic population in 
the United States (Valdez, Athens, Thompson, Bradshaw & Stem, 1994). Based 
on these findings, it has been hypothesized that malnutrition during early foetal 
life may predispose to later metabolic abnormalities and increase the chance of 
development of IGT and NK)DM (Silverman, Rizzo, Green, Cho, Winter, 
Ogata, Richards & Metzger, 1991). 
1,2.8 Complications 
Cardiovascular events, in particular ischaemic heart disease, are the 
leading causes of death in NK)DM. This is partly due to the frequent coexistence 
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ofdyslipidaemia and hypertension in these patients. Hypertension and proteinuria 
are also important risk factors for cardiovascular disease and renal failure in 
diabetic patients OBennet & al, 1995; Pugh, Medina, Cornell & Basu, 1995). 
The main therapeutic objectives in the treatment of diabetes mellitus is to 
achieve normoglycaemia or near-normoglycaemia which are to prevent 
symptoms and has been shown to reduce the incidence and delay the progression 
of microvascular complications (Groop & Pelkonen, 1984). If proper diet, 
exercise, weight reduction, and treatment with maximum dosages of OHA fail to 
optimize glycaemic control, insulin becomes the next treatment of choice. 
The Diabetes Control and Complications Trial ( DCCT ), is the first 
controlled, randomized, long term trial designed to study directly the link 
between metabolic control and complications in a large cohort of patients. In this 
study, (DCCT Research Group 1995) involving over 1400 D)DM patients, those 
treated intensively achieved a HbAic of 7% and had over 60% risk reduction in 
the incidence or progression of retinopathy, nephropathy and neuropathy. This 
was compared to those treated conventionally with a HbAic of 9%. Similar 
findings have also been reported in Japanese NHDDM patients treated with 
insulin (Ohkubo et al., 1995). Most was sectional studies in IDDM and NK)DM 
has also shown that glycaemic control is the main determinant for diabetic 
microangiopathic complications (CrofFord, 1995). Hence, although confirmatory 
24 
1 
evidence is lacking, there is a consensus that tight glycaemic control in NK)DM 
should also be beneficial with improved clinical outcomes. 
1,2,9 Oral Hvvoslvcaemic Agents 
The two most commonly used classes of oral hypoglycaemic agents are 
sulphonylureas and biguanides. Sulphonylureas augment insulin secretion and 
enhance peripheral insulin action possibly due to reduced glucose toxicity. 
Biguanides reduce gastro-intestinal absorption of glucose, enhance glucose 
uptake by peripheral tissue, and reduce peripheral glucose production. The 
alpha-glucosidase inhibitors, such as acarbose, is a non absorbable drug and 
reduces postprandial increase blood glucose by reducing glucose absorption 
from the gut. 
1.2,9.1 Insulin Secretaso2ues 
Sulphonylureas have been the mainstream of therapy for NK)DM for 
more than 30 years. Sulphonylurea drugs are potent agents and reduce blood 
glucose by stimulating insulin secretion, suppressing hepatic glucose production 
and may improve insulin action. Although they are generally well tolerated, 
hypoglycaemia is the major adverse effect. This adverse effect is particularly 
common with the longer acting sulphonylureas, chlorpropamide and 
glibenclamide. Increased age, intercurrent illnesses, reduced caloric intake, renal 
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failure and drug interactions are the main causes of sulphonylurea-induced 
hypoglycaemia (Gerich, 1989). 
L2,9.2 Metformin 
Biguanides were first used in 1957, and metformin has remained a major 
therapeutic agent in the management of MDDM. Unlike sulphonylurea and 
insulin, metformin does not cause hypoglycaemia or weight gain and is therefore 
often considered to be the first line pharmacotherapy for obese NK)DM subjects. 
It is also commonly used in combination with sulphonylruea. It reduces blood 
glucose levels predominantly by improving hepatic and peripheral tissue 
sensitivity to insulin without affecting the secretion of this hormone. Metformin 
also has beneficial effects on serum lipid levels, blood pressure and fibrinolytic 
activity (Dunn & Peters，1995). 
L2.9.3 Alpha-Glucosidase Inhibitors 
Acarbose resembles an oligosaccharide of starch and is a competitive 
inhibitor of this enzyme. With its low systemic absorption, acarbose can be safely 
and effectively used in NK)DM patients with mild disease. It is also used as an 
adjunctive therapy in NTDDM patients treated with diet, sulphonylurea, 
metformin or insulin with improved glycaemic control (Balfour & McTavish， 
1993; Chiasson, Josse, Hunt, Palmason, Roger, Ross, Ryan, Tan & Wolever， 
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1994; Bayraktar, Thiel & Adakr, 1996; Hara, Nakamura, Koh, Sakakibara, 
Takeuchi & Hotta，1996). 
L2,9,4 Insulin Sensitisers 
A new class of OHA, thiazodinediones, an insulin sensitisers, has also 
been shown to be an effective agent in NK)DM with improvement in glucose 
tolerance, blood pressure as well as other cardiovascular risk factors O^olan, 
Ludvik, Beerdsen, Joyce & Olefsky, 1994; Iwamoto, Kosaka, Kuzuya, 
Akanuma, Shigeta&Kaneko, 1996). 
L2.10 Oral Hvp02lvcaentic A2et1t Failure 
Primary drug failure denotes failure to respond to OHA from the outset-
and occurs in around 5% of newly diagnosed MDDM patients. In these patients, 
sulphonylurea therapy does not appear to stimulate the /-cells sufficiently to 
reduce the blood glucose concentration. In most MDDM patients 
sulphonylureas are initially effective in about 70% of patients declining to less 
than 30% after 5 years of treatment. Glycaemic control may improve again in 
some patients with the addition of metformin but eventually many of these 
patients also fail when insulin is then required. Until recently, most of these 
patients are given full insulin treatment substituting previous OHA therapy 
(Riddle, 1992). 
27 
Secondary drug failure denotes failure of effective glycaemic control after 
initial therapeutic success with oral antidiabetic agents (Camerini-Davalos & 
Marble, 1962; Kolterman, Gray, Shapiro & al，1984). This is often due to 
progressive deterioration in /-cell function, and an increase in insulin resistance 
secondary to weight gain and hyperglycaemia (Groop, Schalin, Franssila-
Kallunki, Widen, Ekstrand & Eriksson，1989). Possible causes for secondary 
drug failure are summarized in Table 1.7. Secondary failure occurs in 5-10% of 
NK)DM patients per year. However after 10 years, most NK)DM patients fail on 
oral antidiabetic agents (Groop, Widen, Ekstrand, Saloranta, Franssila-Kallunki, 
Schalin-Jantti&Eriksson，1992). 
1.2,11 Use Of Insulin in NIDDM 
The concept of progressive deterioration of beta-cell function and the 
improved understanding of potential complications associated with 
hyperinsulinaemia has led to a resurgence of interest in alternative methods of 
insulin treatment other than the conventional insulin monotherapy. Exogenous 
insulin therapy improves glycaemic control by decreasing hepatic glucose output, 
and improving peripheral glucose uptake, it also improving insulin resistance and 
insulin secretion by reducing hyperglycaemic glucotoxicity. However, large 
doses are often required to overcome the insulin resistance which is often 
associated with hyperinsulinaemia and weight gain. This may be minimized by 
combining a low dose of insulin with other forms of therapy (Henry, 1996). 
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Table 1.7 : 
Causes ofSecondarv Pru2 Failure in The Treatment with Sulphonvlureas : 
Patient-related factors: 
1. diet failure 
2. poor knowledge of diabetes 
3. sedentary life-style, lack of exercise 
4. stress, intercurrent illness 
Disease-related factors: 
1. insulin deficiency (exclude late-onset IDDM) 
2, insulin resistance 
Therapv-related factors: 
1. inadequate drug dose 
2. sulphonylurea resistance to chronic use 
2 
3. impaired absorption of sulphonylurea during hyperglycaemia 
4. simultaneous use of diabetogenic drugs (steroids，etc,) 
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Suppression ofnoctumal or early moming hepatic glucose production is 
an important aspect in the treatment of NK)DM. Most patients need additional 
drug treatment after they fail the adjustment of dietary intake. OHolman & 
Tumer, 1988). While the patients still have residual /-cell function, 50% of the 
NK)DM patients can achieve optimal glycaemic control by adding sulphonylurea 
(Multicenter Study UK 1985). If fasting plasma glucose targets cannot be 
achieved despite maximal OHA therapy, insulin treatment is then required. This 
can be given as a supplement, usually as a single evening injection. Alternatively, 
the patient can be switched over to full substitution with insulin replacement 
therapy. 
1.2.12 Combination Therapy 
Optimal insulin regimens for NK)DM patients with secondary failure 
remain controversial (Karlander, Gutniak & Efendic, 1991; Johnson, Wolf & 
Kabadi, 1996). If near-normal glycaemia is to be achieved, many NK)DM 
patients will need insulin therapy. When full insulin replacement therapy is not 
feasible, reducing the fasting blood glucose level towards normal with a single 
daily insulin dosage giving either as a supplement or in combination with oral 
agents may be considered (Rachman & Turner，1995). 
Insulin-treated subjects often have poor vascular outcomes. This is partly 
due to their longer and more severe disease (Sasaki, Uehara, Horiuchi & 
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Hasagawa, 1983; Davidson, Zwagg, Cox, Delcher, Mainzer, Baggett & Runyan, 
1984; Kleinman, Donahue, Harris, Finucane, Madans & Brock, 1988) and 
poorer glycaemic control fKlein, Klein, Moss, Davis & DeMets，1988). 
Triglyceride and HDL levels can be adversely affected in those with higher 
circulating insulin levels (Santen, Willis & Fajans, 1972; Standi & Janka’ 1985). 
Atherosclerotic complications and hypertension have also been associated with 
peripheral hyperinsulinaemia (Colwell, 1985; Landsberg, 1987; Stolar, 1988). 
Nevertheless, most medical practitioners hold the view that the benefits of 
improved glycaemic control outweigh the potential adverse effects of insulin on 
vascular disease. In non-insulin deficient NK)DM patients, a compromise may be 
obtained by administrating as little insulin as possible in reaching glycaemic 
targets. Several reports show the effectiveness of the combination of bedtime 
insulinAiay-time sulphonylurea (Reich, Abraira & Lawrence, 1987; Riddle, 1988; 
Riddle, Hart, Bouma, Phillipson & Youker，1989; Trischitta, Italia, Borzi, 
Tribulato, Mazzarino, Squatrito & Vigneri, 1989; Groop et al., 1990). Patients 
responding to the regimen avoid the need of second injection of insulin and may 
achieve an improved portal / peripheral ratio of day-time insulin levels than with 
insulin alone. There may be a further reduction in insulin requirements as HbAic 
falls (Groop etal, 1990). 
Since sulphonylurea can enhance endogenous insulin secretion, less 
exogenous insulin is needed (Holman, Steemson & Turner, 1987). Combination 
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insulin therapy with patients with secondary drug failure may also improve 
insulin secretory reserve as a result of improved glycaemic control and reduction 
of "glucotoxicity". However, these benefits might be of short term (Yki-
Jarvinen, Nikkila, Helve & Taskinen，1988). 
Rationales for combining insulin and oral drug therapy is based on a 
better understanding of the pathophysiology ofNK)DM and the modes of action 
of the oral drugs available and some of the reasonings are as follows : 
1. NK)DM is heterogeneous with varying degrees of insulin-deficiency and 
insulin-resistance. High doses of exogenous insulin are required in patients 
with significant resistance to insulin action. 
2. Peripheral insulin delivery leads to peripheral hyperinsulinaemia which may 
contribute to the pathogenesis of macroangiopathic complications. 
3. Sulphonylureas stimulate insulin release directly into the portal vein thus 
maximizing the benefit which can be obtained from endogenous insulin 
secretion 
4. Insulin may have synergistic effects with other oral agents. Metformin 
improves glucose metabolism and insulin sensitivity. Alpha-glucosidase 
inhibitors reduce the amounts of insulin needed to control postprandial 
hyperglycaemia 
(Scheen, Castillo & Lefebvre, 1993) 
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There are some evidence showing that combination of insulin and 
sulphonylurea improves glucose profile significantly when compared to full 
replacement insulin treatment. (Kabadi & Kabadi, 1995) Others, have doubts 
about the effectiveness ofthis type of therapy. (Ravnik-Oblak & Mrevlje’ 1995). 
(Clauson, Karlander, Steen & Efendic, 1996). 
Combination of an evening insulin injection and OHA before meals 
appears to be most beneficial in diabetic patients who still have some residual 
insulin secretory capacity (Sheen, Castillo & Lefebvre, 1993). Potential benefits 
include less weight gain and less peripheral hyperinsulinaemia. Compared with 
twice-daily or multiple-injection insulin therapy, combination treatment is also a 
more acceptable regimen for many of these NK)DM patients previously treated 
with oral agents (Yki-Jarvinen etal., 1992; Soneru, Agrawal, Murphy, Lawrence 
& Abraira, 1993). Other medical practitioners used an evening injection of long 
acting insulin as a primary treatment for NK)DM (Riddle, 1985). 
Other treatment strategies, including insulin monotherapy, the 
combination of insulin and day-time sulphonylurea with or without biguanides 
have been proposed by various researchers (Peacock & Tattersall, 1984; 
Taskinen, Sane, Helve, Karonen, Nikkila & Yki-Jarvinen, 1989; Groop, Groop 
& Stenman，1990; Goo, Garson & Bjelajac，1996); and also among the Chinese 
in Taiwan (Chuang, Lu, Su, Wu, Tai & L 4 1992). NK)DM patients with 
peripheral insulin resistance often have high evening as well as fasting plasma 
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glucose levels (Groop et al., 1992). Glycaemic control in these patients can often 
be improved by using a long-acting insulin preparation such as human ultralente 
(Gutniak, Karlander & Efendic, 1987; HoIman et al., 1987). The rationale for 
use of bedtime insulin is to suppress overnight hepatic glucose production to 
achieve a normal to fasting plasma glucose (Taskinen et al., 1989). Once fasting 
plasma glucose is lowered, the plasma glucose excursions during the day will be 
reduced ^lolman & Tumer，1977). 
Some of the previous conflicting results on combination insulin-OHA 
therapy may be attributable to uncontrolled trials, heterogeneous patient 
selection, small sample sizes and studies of short duration. Furthermore, many of 
these studies involve patients who required full substitution insulin previously 
and then later changed over to combined therapy (Lotz, Bachmann & Mehnert， 
1988; Pugh, Wagner, Sawyer, Ramirez, Tuley & Friedbei^, 1992) These patients 
were likely to have all failure and unlikely to respond to low dose treatment 
It is presumed that the mechanisms by which glucose causes 
complications is the same in NIDDM as in LDDM, (Lebovitz, 1994) and this is 
supported by. the results of the Kumamoto Study (Ohkubo et al., 1995) An 
intervention trial insulin treated NK)DM patients also demonstrates similar 
beneficial effects of optimal glycaemic control as that to The Diabetes Control 
and Complications Trial (DCCT). 
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Against this background, a longitudinal study was undertaken to compare 
the efficacy, drawback, acceptance of treatment, and quality oflife in 55 Chinese 
MDDM patients with secondary OHA failure receiving insulin treatment either 







This study used only registered medications ( e.g. human insulin ) 
indicated for the treatment of diabetes. It was performed in accordance with the 
protocol which was approved by the Ethics Committee of The Chinese 
University of Hong Kong, and in accordance with the revised Declaration of 
Helsinki ( 1983 ) governing experimentation with human volunteers. All subjects 
gave written informed consent using a consent form which was translated into 
Chinese before inclusion in the trial. An example of the consent form is shown in 
appendix 1 
2.2 OBJECTIVES 
The aims of the study were : 
a. To examine 50 - 100 subjects and compare the effects of two insulin 
treatment regimens on metabolic control in Type II diabetic patients with 
\ 
documented secondary failure of glycaemic control with oral 
hypoglycaemic agent therapy. 
The two resimes used were: 
i. Combination Therapy With this regime, insulin 
supplementation using a bedtime dose of the intermediate acting 
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Protaphane ( Isophane ) insulin was given, with continuation of 
existing oral hypoglycaemic therapy. 
ii. Insulin Substitution Therapy : With this regime, full insulin 
substitution was given and previous oral hypoglycaemic agent 
therapy was discontinued and replaced entirely with twice daily 
insulin injections. 
b. To compare the acceptability of the two regimens 
c. To compare subjective well-being and quality oflife while using 
the two regimens in an Asian population 
.13 OVERALL DESIGN 
The main body of the study utilized a randomized open, parallel design 
which consisted of 5 visits and 4 evaluation periods. A flow diagram describing 
the various stages of the study and the overall study design is shown in Table 
2.1. The same members were responsible for all assessments made through out 
the study (i.e. physician, certified research nurse & dietitian). 
2.3.1 Selection Of Patients 
2,3,L1 Inclusion Criteria 
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Table2.1 : Overall desisn ofthe studv (revised from the orisinal protocol) 
Name: Randomization 林•• 
D.O.R : Sex/Age: Phone: 
Visit 1 2 3 4 5 
Recruitment Run-In 3-month 6-month 18-monih 
Date / / / / / / / / / / 
Weight X X X x 
Height X X x x 
BP X X X X 
FPG X X X X 
HbAlc X X X X 
Fructosamine x x x x 
Total Cholesterol x x x x 
Triglyceride x x x x 
HDL X X X X 
LDL X X X X 
Phisma C-peptide: fasting x x 
stimuUaed x x 
CompUte bUfod Count x x 
Renal/Liver Function x x 
Questionnaire 
a. WeU being x x x x 
b. AcceptabiUty of InsuUn x x x x 
History x 
CUnical Exam x 
Diet / exercise reinforced x 
Home BUfod gUicose profiles checked x x x x 
Hypoglycaemia check x x x x 
Drug compUance stressed / intensified x x 
HBG monitoring taught / reinforced* x x x x x 
Injection techniques taught/reinforced x x x x x 
InsuUn Given x x x x 
Machine Loan sheet signed x 
Consent signed x 
ExpUmatin of reasons for study given x 
Hospital Record Renewed x 
Inclusions / Excbisions checked x 
Phone Contacts Dates (p.r.n.): / / . / / . / / . / / . / / 
* Home Mood gbu:ose monitoring taught / reinforced 
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Subjects with known NIDDM aged above 20 years of age were 
assessed for entry to the study. All subjects included were receiving a maximum 
dose of sulphonylurea with or without metformin. Subjects were randomized to 
the study iffasting plasma glucose (FPG ) remained greater than or equal to 7.8 
mmoVL or random plasma glucose remained greater than or equal to 11.1 
mmol/L at the end of an initial assessment period during which reinforcement of 
diet, exercise and drug compliance was provided as described in Chapter 2.3.3.1. 
2,3,1.2 Exclusion Criteria 
Type I diabetics, or diabetics already using insulin were excluded. 
Patients with a history of unstable metabolic control ( hypoglycaemia or 
ketoacidosis ) were also excluded, as were patients receiving lipid-lowering 
therapy and patients known to have concurrent severe illnesses or diabetic 
complications ( for example, proliferative retinopathy, severe maculopathy ). 
Other exclusion criteria included known ischaemic or other heart disease ( 
angina, history of myocardial infarction and congestive heart failure), peripheral 
vascular disease, renal failure ( creatinine > 150 i^mol/L )，or hepatic disease. 
Night shift medical practitioners and those with known alcohol consumption 
exceeding 50gm / day were also considered not eligible to enter the study. 
2,3.2 Recruitment Period 
2.3.2.1 Screening Period 
40 
During their regular visit to the Prince of Wales Hospital Diabetes 
Specialty Clinic, the patients were screened, according to the inclusion and 
exclusion criteria described, above for suitability for entry into the study. The 
hospital records were reviewed. The diagnosis of secondary OHA failure was 
documented using the criteria described above. Questions regarding duration of 
DM, previous use of insulin, details of present compliance to diet as adviced by 
the dietitian, and details of current OHA treatment were checked. If the patient 
met the entry criteria and agreed to enter the study, full verbal explanation of the 
study protocol ( Appendix II ) was given to the patient by the certified research 
nurse in Chinese and a consent form ( Appendix I ) written in Chinese was 
signed. The explanation given included general explanation as to why insulin 
treatment was required in addition to explanation of the study itself. Visit 1 
appointment was then given to the subject at the Metabolic Investigation Unit ( 
Endocrinology Research Unit )• Page 1 of the clinical record form ( CRF ) was 
also completed ( see Appendices IV & V as an example). 
2,3.2,2 Pre-Run-In Period ( Visit 1) 
Following the screening period, patients fulfilling the inclusion criteria ( 
Chapter 2.3.1.1 ) were seen by the physician and the certified research nurse for 
diabetes management during a 6-week initial assessment period prior to the 
introduction of insulin therapy using either of the two regimens described in 
Chapter 2.2. Two different types of home blood glucose monitoring machines ( 
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details ofthe types of machines can be found in Chapter 2.6 and Appendix XIV ) 
were loaned to the patients and the techniques of blood glucose monitoring 
taught. The patients were asked to carry out measurements on 2 days per week. 
The recommended times were before breakfast and 2 hours after lunch and/or 
dinner. Injection technique and knowledge of hypoglycaemic attacks were also 
taught. Conventional life style modification measures ( diet and exercise ) were 
reinforced. Drug compliance was stressed and intensified. If symptomatic 
hypoglycaemia occurred, additional checks were requested. 
2.3.3 Run-In Period ( Visit 2 ) = Baseline Evaluation 
Before any changes to the original OHA regimen were made and two 
weeks prior to randomization, the subjects were investigated to document their 
physical status and pancreatic reserve. This was carried out at visit 2. Venous 
blood was drawn for baseline evaluation. Measurements of fasting plasma 
glucose ( FPG )，glycosylated haemoglobin ( HbAic ), and glycated plasma 
protein concentration ( fructosamine ) were taken. Plasma C-peptide was 
measured, both fasting and 6 minutes following administration of glucagon 1 mg 
intravenously. Page 2 of the CRF was completed ( Appendix VI). A structured “ 
well-being" questionnaire was also administered in Chinese by the research 
nurse. A Visual Analog Scale ( VAS ) with a range of 0 - 100 with 100 being 
the maximum was used to evaluate sleep, general well-being both in the 
morning and evening, socialization, activity level and time for leisure, to produce 
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a score for quality of life. Better control of DM can result in improvement of 
their quality of life even in the short term as a direct result of lowering glucose 
concentration and there by relieving symptoms. Over the long term reduction of 
complications would also be expected to improve quality of life. The 
questionnaire is shown in Appendix VII and Appendices IX’ XI, XIII, Part 1. 
Pages 3, 5, 7，9 of the CRF was completed at this time. 
A second questionnaire, also using a VAS scale, was administered to 
assess acceptability of insulin injections. Anticipated pain, inconvenience and 
troublesomeness from injections were also assessed and recorded on pages 5, 7, 
9 ofthe CRF ( Appendices IX，XI, XIII, part II ). 
Both of these questionnaires were re-administered at each of the 
evaluation periods. 
2.3.3.1 Stabilization 
A maximum duration of 8 weeks was allowed for insulin dose 
stabilization up to maximum allocated closes of 26 units and 84 units 
respectively for the Combination and Insulin Groups. This is an arbitrary decision 
based on a calculated reasonable titration period. Target fasting plasma glucose 
was less than 7.8 mmol/L on 2 consecutive occasions and also 2-hour 
postprandial glucose <11.1 mmolyL for both groups. Once stabilized during the 
Run-In Period, subjects were asked to continue their treatment unchanged 
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unless otherwise decided by the physician during review at 3 months. At the end 
ofthree months, the second series ofinvestigations were conducted. 
Between visits, the subjects were regularly reviewed by the research 
nurse ( myself ) through telephone contact. Only minor adjustments were made 
and extra requested visits given if indicated e.g. for hypoglycaemia. At the 
subsequent 3’ 6 and 18-months visits, the results of home blood glucose 
monitoring were reviewed and episodes ofhypoglycaemia were recorded. Body 
weight and fasting blood samples for glucose, HbAic, fructosamine and lipids 
were measured again. 
2.3,3.2 Randomization 
At the end of the initial assessment period and following review of the 
laboratory results ( FPG, HbAic , fructosamine, complete blood count, serum 
creatinine and liver function tests )，diet and home blood glucose profiles, those 
subjects still fulfilling the inclusion criteria ( Chapter 2.3.1.1 ) were randomized 
consecutively and alternately to one of the two treatment groups. They then 
followed an eighteen months schedule during which they were reviewed while 
receiving either OHA plus insulin ( Combination Group ) or insulin alone ( 
Insulin Group ). An additional review of status at approximately 48-months was 
also performed. 
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Patients were randomized according to the terminal digit of their 
admission number. Thus, odd numbers were assigned to the Combination Group 
and even numbers were assigned to the Insulin Group. 
The number of subjects undergoing randomization after re-evaluation ( # 
55 ) was lower than the number originally recruited ( # 100 ). The reasons for 
this will be explained in detail in Chapter 3，Section 2 under results. 
2,3.3,2.1 Combination Group ( OHA + Insulin ) 
For the patients treated with supplementary insulin plus OHA ( 
Combination Group )，OHA therapy was not changed following randomization 
and supplementary insulin was added as described below. All patients continued 
with their pre-existing sulphonylurea therapy, with or without metformin, the 
dosage having been adjusted to a maximal daily dose as defined by the protocol 
and not exceeding the manufacturer's recommendation. As shown in Table 2.2, 
20 mg/day was considered to be the maximum dose for glibenclamide, 30 
mg/day for glipizide and 320 mg daily was considered as the maximum dose for 
gliclazide according to local and European experience (Lebovitz & Melander， 
1992) and the relatively lower body weight of Chinese patients ( mean 土 SD, 
60.4 土 13.3 kg )( Table 3.1 ). Dosages of metformin were more variable 
reflecting tolerability, gastrointestinal side effects being dose-limiting in a 
considerable number of patients. 
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TableZ2 : Maximal dailv recommended doses ofOHA 
Sulvhonvlureas Maximum dose/dav 
Chlorpropamide 250mg 500 - 750 mg 
(e.g. Diabinese) (2 - 3 tabs) 
GUbencUunide 5 mg* 20 mg 
(e,g. Daonil, EugUicon ) ( 4 tabs) 
Glidazide80mg* 320mg 
(e.g, Diamicron) (4tabs) 
GlipizideSmg* 30mg 
(e.g. Minidiab ) ( 6 tabs ) 
Tolbutamide 500 mg 2000 mg 
(e.g. Rastinon ) ( 4 tabs ) 
Bisuanides 
H^^akMMM_SMMM 
Metformin SOOmg* 3000 mg 
(e.g. Glucophage ) ( 6 tabs ) 
* Used in this study 
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Supplementary insulin using a single injection of protaphane HM insulin ( Novo. 
Nordisk A/C, Denmark ) was added ( given by self-injection ) at an initial dose 
of 6 units administered 30 minutes prior to retiring to bed ( or 11 p.m. at the 
latest ) in order to suppress overnight and early morning gluconeogenesis. The 
starting dose of 6 units was then adjusted every 1-2 weeks, increasing by 
increments of2-4 units ( or by 0.2 U / kg in patients weighting less than 50 kg )， 
until either the glycaemic targets were achieved, or up to a maximum allowable 
dose of26 units at night (i.e. a total of 4 x 4 units increments ) as defined by the 
protocol. 
No additional attempt was made to adjust the post-lunch plasma glucose 
by altering the timing of the dose of the insulin injection, or by adding a pre-
breakfast injection. 
2,3.3.2.2 Insulin Group (Insulin Alone) 
For the group treated with full insulin therapy substitution, OHA therapy 
was discontinued and insulin was commenced. As a general guideline, a usual 
recommended dose of insulin was commenced at 16 U or 0.2 - 0.3 U/kg given 
30 minutes before breakfast. The insulin dose was split into two injections per 
day when the total daily requirement exceeded 24 units. Adjustment was made 
every 1-2 weeks using increments of 4-8 units. A maximum duration of 8 weeks 
was allowed for stabilization up to maximum allowable doses of 84 U/day as 
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defined by the protocol. Actrapid HM, Actraphane H M or Protaphane HM, 
insulin were used either once or twice daily, to achieve the glycaemic targets of 
a fasting plasma glucose below 7.8 mmoVL and/or 2-hour post lunch plasma 
glucose below 11.1 mmol/L. 
2.3,4 Evaluation Periods ( Visits 3 to 5) 
( 
Following randomization to either group, all patients were reviewed 
again by a dietitian for further reinforcement of diet and exercise, and any 
adjustment of snacks after introduction of insulin. Home blood glucose 
monitoring and insulin injection techniques were checked again. The patients 
were asked to keep a record of home blood glucose profiles and episodes of 
hypoglycaemia. Visits 3 and 4 assess the 3- and 6- months progress by regimen, 
glycaemic control, HbAic, fructosamine, lipid profiles, total insulin dosages, 
weight gain, B M I were calculated statistically and compared to the baseline 
assessment along with analysis of the scores of actual pain and inconvenience 
obtained from the Visual Analog Scale using the questionnaires. In addition, 
well-being after insulin and desire to continue with insulin were recorded. In 
addition, C-peptides, both fasting and stimulated were reassessed at visit 5 at 
approximately 18-months period. 
At approximately 48-months, the latest status at the time of writing of 
the studied subjects was reviewed and all biochemical values and their chemistry 
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values ( i .e. glycaemic control, HbAic, lipid profile ) and clinical parameters ( 
weight change, body mass index, blood pressure, current dosage oftotal insulin ) 
were re-evaluated. 
2.3.5 Studv Medications 
The f0ll0win2 insulin preparations were used : 
PROTAPHANE HM : Isophane “ NPH" Hisulin. This was initially 
used for the day-time injection, to lower blood glucose during the day, and for 
the night-time injection, to provide intermediate duration of insulin action 
overnight. 
ACTRAPID HM : soluble “ regular" insulin. This was used instead of 
actraphane H M or in addition to protaphane HM, in patients in the Insulin Group 
with high postprandial glucose values on Protaphane alone. 
ACTRAPHANE HM : 30% Soluble “ Regular" ^ s u l i n 
premixed with 70% isophane “ NPH" insulin. This was used for both day-time 
and night-time injections instead of protaphane when an additional short acting 
component was required in addition to the more delayed intermediate action of 
protaphane alone. 
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Protaphane ( H M ) insulin ( Novo-Nordisk, Copenhagen ) was used as 
the first choice insulin in both groups of patients. This is an isophane human 
insulin preparation with an intermediate duration of action. In subjects receiving 
full insulin substitution the short acting insulin preparation actrapid ( H M ) ( 
Novo-Nordisk, Copenhagen ) was added i f required to control post-prandial 
blood glucose excursions The combined preparation, actraphane ( H M ) ( Novo-
Nordisk, Copenhagen ) was also selected for use i f deemed appropriate. This 
preparation contains a mixture of 30% actrapid ( H M ) ( soluble insulin ) and 
70% protaphane ( H M ) (isophane insulin ). 
2.3.6 Clinical Assessments 
Dosages for OHA and insulin, hypoglycaemia, weight ( kg ) and height ( 
m )，were recorded at each visit. Body Mass Index ( B M I ) was then calculated 
according to the formula, weight / height ^ ( kg / m^ ) for all visits. Blood 
pressure values at the 21- and 51-months were compared with baseline values 
prior to randomization. The structured questionnaires on general well being and 
insulin acceptability were recorded at each of the follow-up visits. 
2,4 WITHDRAWALS 
Patients from the Combination Group who failed to achieve target 
glucose values despite reaching the maximum-allowed dose of 26 u Protaphane 
HM in a single injection at night were considered as having "combination therapy 
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failure" and were changed to full insulin substitution with two injections of 
insulin per day and withdrawal of OHA. Details were documented on the Case 
Record Forms (CRF ) and included in the subsequent analysis according. 
Members of the insulin group who failed to achieve control at the 
maximum 84 units per day continued on that dosage throughout the study until 
completion of the study. 
25 INVESTIGATIONS 
Baseline investigations included fasting plasma glucose, glycosylated 
haemoglobin ( HbAic ) , fructosamine, and lipoprotein profiles ( total 
cholesterol, triglycerides and HDL-cholesterol ). Insulin secretory reserve was 
assessed at baseline by measuring serum C-peptide concentration in the fasting 
state. Glucagon ( 1 mg ) was then administered by intravenous injection and 
blood was drawn for a second ( glucagon - stimulated ) C-peptide measurement 
exactly 6 minutes later. Renal function tests, liver function tests and complete 
blood count were also checked. Fasting plasma glucose, HbAu, fructosamine, 
and lipoprotein profiles were repeated at each interim visit at 3, 6, and 18-
months. ( Appendices VIII , X, X I I ) Page 4，6, 8 ofthe CRF were completed. At 
approximately 48-months, chemistry values and clinical parameter ( blood 
plasma, HbAic, lipids, BMI and total insulin ) were reassessed. 
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Z6 ANAL YTICAL METHODS 
Home measurements of blood glucose were performed using either the 
Boehringer Mannheim ( BM ) Reflolux S ( Range 0.5 - 27.7 mmoH.) ’ or Ames 
Glucometer GX machines ( Range 1.4 - 22.1 mmol/L )• ( see Appendix XIV for 
Technical Specifications. ) The majority ( 92% ) of subjects used the Reflolux S 
machine. 
Plasma glucose was measured by a glucose oxidase method ( Diagnostic 
Chemicals Ltd. reagent kit, Canada ). Glycosylated haemoglobin ( HbAic) was 
determined by gel electrophoresis ( Ciba Corning Diagnostics Corp. Palo Alto, 
CA. U.S.A. ) with a laboratory normal reference of 4.6 - 6.4%. Fructosamine 
was measured using a centrifugal analyzer ( Cobas Bio, Hoffman-La Roche, 
Basle ). The laboratory normal range is 180-320 ^moLT.. The inter-assay 
coefficients of variation ( CV ) were as follows : Plasma glucose was 2.0% at 
6.6 mmolyL; HbAic was 3.1% at values below 8.5%; fructosamine was 2.0% at 
151 ixmoUL. 
Plasma C-peptide concentrations were measured by double-antibody 
radio-immunoassay (Novo Nordisk A/S, Copenhagen, Denmark ) with an intra-
assay CV of3.4% and inter-assay CV of 9.6%. The lower detection limit was 
0.02 mmolyL. Plasma insulin was measured by radio-immunoassay ( Novo 
Nordisk A/S, Copenhagen, Denmark ). The intra-assay and inter-assay 
coefficients of variation were 4.3% and 13.8% respectively. The detection limit 
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was 3 ^U/ml. Serum lipids including total cholesterol, high-density lipoprotein ( 
HDL ) cholesterol, and triglyceride concentrations were measured enzymaticaIly 
(Cobas Mira, Hoffinan-La Roche, Basle ) Their “ desirable ranges “ are <5.2, 
>1.0, <2.0 mmol/L respectively. The inter-assay coefficients of variation were 
1.9% at 6.4 mmol/L for total cholesterol; 2.6 % at 1.9 mmol/L for triglyceride 
and 5.4% at 0.86 mmoLL for HDL. LDL were calculated using the 
Friedewald's formula (Friedewald, Levy & Frederickson, 1972) 
2 7 STATISTICAL ANALYSIS 
The raw data obtained from the clinical trial were entered into an EBM 
Thinkpad Pentium 755CX personal computer and all statistical analyses were 
performed using a SPSS version 6.0 software package. Al l tables were created 
with Microsoft Excel version 5.0; all graphs and diagrams were created with the 
Jandel Scientific Software Sigma Plot for Windows version 3.0. All data, were 
expressed as mean 土 SD or geometric mean x7+ antilog SD. 
Two tailed sample Student's t-tests were used to determine i f the 
subjects in the two treatment groups were comparable at entry regarding mean 
age, height, weight, body mass index ( B M I )，duration of diabetes, fasting 
plasma glucose ( FPG )，fructosamine, glycosylated haemoglobin ( HbAic )，and 
lipid concentrations. Data not following a normal distribution were also validated 
using a non-parametric test ( Wilcoxon's rank-sum test ). Plasma triglyceride 
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concentrations were logarithmically transformed due to skewed distributions. 
The results were expressed as mean 土 SD with 95% confidence intervals.; p < 
0.05 was considered statistically significant • With laboratory data as a dependent 
variable, a repeated-measurement analysis of variance (ANOVA) was performed 
to test for differences between the two treatment groups and between visits. 





3.1 S TUD Y POPULA TION 
Patients screened for entry were recruited from the Diabetic Clinic at The 
Prince of Wales Hospital, the teaching hospital of The Chinese University of 
Hong Kong, which serves a catchment population exceeding 1 million. 
A total of 100 consecutive Chinese NK)DM patients age > 20 years, who 
after treatment with a maximum dose of sulphonylurea 土 metformin, had a 
persistent fasting plasma glucose > 7.8 mmo^L entered the initial assessment 
phase, the pre-run-in period. Forty-five were excluded from the study at the end 
ofthis phase as they no longer fulfilled the inclusion criteria. Of these, 22% ( 22 / 
100 ) had improved after a 6 week period of reinforcement of diet, exercise, and 
/ or better drug compliance together with self home blood glucose monitoring. 
Five were excluded for supervening acute medical illnesses. Eighteen refused 
participation for social or personal reasons, the most common reasons being the 
inability to comply with the frequent visits and objections to receiving 
injections. These results emphasize the importance of potentially correctable 
factors, such as diet, exercise and drug compliance, in the management of OHA 
failure in Hong Kong Chinese NK)DM patients. 
Following this initial assessment phase, 55 subjects fulfilled the inclusion 
criteria and were randomized for entry into the study. Their baseline 
characteristics are shown in Table 3.1 . 
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Table 3.1 : The clinical characteristics at baseline of all randomized subiects 
before commencement of insulin treatment. Data are shown as mean 土 SD 
(range、with * Geometric mean x/+ antilog SD. 
~ ^ 18M, 35F 
Age (years) 53.9±12.6(29-81) 
Duration o f D M (years) 9.0 土 4.9 (2 - 26) 
f 
Height (cm) 158.0 土 8.4 (144 - 180.5) 
Weight (kg) 60.4 土 13.3 (38.5 - 122.5) 
BMI (kg/m2) 24.20土4.31(16.3-38.7) 
BP ( mmHg ) Systolic 137.82 土 22.71 (106 - 220) 
BP ( mmHg ) Diastolic 76.90 土 9.66 (56 - 96) 
C-peptide (ng/ml) fasting 2.01 土 1.03 (0.08 - 4.79) 
C-peptide (ng/ml) 6 ” post-glucagon 3 . 6 2 土 2 . 0 7 ( 0 . 0 8 - 1 0 . 2 0 ) 
FPG (mmol/L) 13.5 土 3.2 (8 - 20) 
HbAic ( % ) 10.4±1.6 (6.1-14.2) 
Fructosaminq ( ^imoLl^ ) 471 土 90 (330 - 689) 
Total Cholesterol (mmoH.) 5.81 土 1.42 (3.5 - 10.4) 
Fasting triglyceride* (mmoH.) 1.29 x / + 1.96 (0.28 - 6.89) 
HDL-cholesterol (mmoLT：.) 1.29 土 0.32 (0.81 - 2.20) 
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Further analysis of the baseline data was performed using linear 
regression analysis ( Table 3.2 )• BMI was positively correlated with glucagon ( 
1 mg, I.V. ) stimulated C-peptide levels ( r = 0.37’ p = 0.01 ); and both were 
positively correlated with fasting triglyceride ( r = 0.61，p = 0.001 and r = 0.58， 
p = 0.001 respectively ) and negatively correlated with HDL-cholesterol ( r = -
0.37, p < 0.01 and r = - 0.36, p = 0.01 respectively ). Only 12 patients ( 29% ) 
had glucagon-stimulated C-peptide values < 2.14 ng/ml. Baseline C-peptide also 
correlated significantly with fiiictosamine but not with HbAic and fasting plasma 
glucose. Significance or lack of significance of the correlation coefficients needs 
to be taken in the context of the small sample size. 
3.2 RANDOMIZATION 
Twenty-eight patients were randomized to receive combination therapy ( 
Combination Group ) with an unchanged oral hypoglycaemic agent regimen plus 
insulin ( Isophane Insulin suspension : Protaphane HM, Novo Nordisk ) ( 
Chapter 2.8 ) given 30 minutes before going to bed or before 11 p.m. Twenty-
seven subjects were randomized to full insulin substitution (Insulin Group ) and 
these subjects discontinued their oral hypoglycaemic agents. Both groups 
received insulin therapy as described earlier ( Chapter 2.3.3.2.1 and 2.3.3.2.2). 
There were 2 subjects discontinued after randomization and they will be 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comparison ofthe baseline characteristics of the subjects randomized to 
each ofthe combination and insulin groups are summarized in Table 3.3 and can 
be seen to be similar. The sex, age, duration of DM, height, weight BMI, 
FPG and C-peptide of the study subjects are compared in both groups at 
baseline. The mean duration of diabetes for the two groups is 9.0 土 4.9 years.( 
Table 3.1 ) The subjects randomized to the Combination Group are slightly 
older ( mean age 57.04 土 10.57 years ) whereas those in the Insulin Group are 
slightly heavier ( body weight 64.23 土 16.72 kg with corresponding body mass 
index 24.58 土 4.67 kg / m^ ). However, these differences are not statistically 
significant. The only significant difference found at baseline is the lower fasting 
C-peptide concentration in the Insulin group. The glucagon-stimulated C-peptide 
concentration is also lower in the Insulin Group but the differences just fail to 
reach statistical significance. 
Out of the total 55 patients who were on the study, thirty-four of these 
patients had combined OHA therapy with maximum doses of sulphonylurea (i.e. 
either glibenclamide or glipizide or gliclazide ) plus metformin 0.5 - 2.0 g/ day. 
Table 3.4 summarizes and compares the oral hypoglycaemic agent therapy 
received by .the two groups at the time of randomization. There were no 
significant differences between the 2 groups in relation to their sulphonylurea 
therapy ( including dosages ) and equal numbers ( # 17 ) in each group were 















































































































































































































































































































































































































































































































































































































































































































































































































3.3,1 Indices OfGlvcaemic Control And Lipids 
3,3,1.1 Glucose Values 
Following the introduction of insulin therapy, fasting plasma glucose 
(FPG ) showed significant improvement within both groups. 
For the Combination Group, fasting plasma glucose decreased from the 
baseline mean of 13.5 土 2.7 to 8.9 土 3.0 mmoLTL at 3-months ( p < 0.001 )，to 
8.6 土 2.5 mmoVL at 6-months ( p<0.001 ) and to 8.4 土 3.6 at 21-months ( p < 
0.001 )• 
For the Insulin Group, fasting plasma glucose decreased from the 
baseline mean of 13.5 土 3.6 to 7.5 土 3.0 mmoVL at 3 months ( p < 0.001 )，to 
9.8 土 3.5 mmoH. at 6 months ( p < 0.001 ) and 9.4 土 3.8 mmoVL at 21-months 
(p<0.001 ). 
Thus although both groups showed improvements, FPG decreased more 
in the Insulin Group than in the Combination Group during at the first 3-months 
period, ( mean 7.48 vs 8.9 mmoUL respectively ) but rose to a higher value at 6 
months ( 9.78 vs 8.6 mmoVL respectively ). However, no significant difference 
was observed between the 2 groups at either time point. Similar values were 
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maintained at a mean duration of 21-months for both groups. Details can be 
found in Table 3.5a and 3.5b. 
3.3.1.2 Glycosylated haem02l0hin (HbAu) and 
GlvcatedPlasma Protein Concentration (Fructosamine) 
In keeping with the falls in fasting plasma glucose, both groups also 
showed significant improvement of both fructosamine and glycosylated 
haemoglobin ( HbAic ). Fructosamine demonstrated a significant difference 
between the two groups ( p < 0.01 ) at the 3-months evaluation. These results 
are shown separately for each group in Table 3.5a and 3.5b and are compared 
directly in Figure 3.1. 
3,3,1,2.1 Glycosylated haemoslohin (HbAu) 
Glycosylated haemoglobin (HbAic ) decreased from 10.2 土 1.3 to 8.4 土 
1.1 % at 3-months ( p < 0.001 ) to 8.7 土 1.3 % at 6-months ( p < 0.001 ) and to 
8.9 土 1.3 ( p = 0.001 ) at 21-months in the Combination Group and from 10.7 土 
2.0 to 7.8 土 1.4 % at 3 months ( p < 0.001 ), to 8.4 土 1.8 % at 6 months ( p < 
0.001 ) and to 8.8 土 1 % ( p = 0.001 ) at 21-months in the Insulin Group. Both 
groups showed significant improvement at 3 - � 6 - and 21-months although there 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fisure 3,1, ( mean 土 SD) 
Fastine blood glucose (Al fructosamine (B) andHbA^ (0 concentrations 
at baseline. 3. 6. and 21 months after stabilization of insulin dosaee 
in patients receivine either combination therapv or insulin therapv alone, 
(+P <•• 05 between the groups; *P = 0.001, **P < 0.001 vs baseline) 
^ 16 ~| 
A I 1 4 - T . 
_ _ 
B 600 ] + 
_ l _ 。 _ _ 
Baseline 3 mths 6 mths 21 mths 
I I Combination therapy ^ ^ Insulin therapy 
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At 51-months, HbAic continued to be significant with a mean value of 
9.18 土 1.68o/o ( p < 0.01) in the Combination Group and a mean value of9.62 土 
2.32% ( p < 0.01) in the Insulin Group. 
No significant differences were observed between the groups at any time 
point including the period at a mean 51-months. 
3.3.LZ2 GlvcatedPlasma Protein Concentration 
(Fructosamine ) 
Both groups also showed significant falls in fructosamine concentration 
compared to baseline ( Tables 3.5a and 3.5b )• At 3 months, fructosamine fell 
further in the Insulin Group than the Combination Group, with a reduction 159 土 
31 vs 93 土 40 YLmdUh respectively. ( P < 0.01 )，although similar concentrations 
were maintained at 6 and 21-months between the groups. 
For the Combination Group, fructosamine fell from 458 土 97 at baseline 
to 365 土 57 ^moLL at 3 months ( p < 0.001 ) to 371 土 79 i^moLO：. at 6 months ( 
p < 0.001 ) and to 352 土 64 ^moUL at 21-months ( p < 0.001 ) as shown in 
Tables 3.5a and 3.5b and Figure 3.1. 
For the Insulin Group, fructosamine fell from 484 土 83 at baseline to 325 
土 52 ^moLO:. at 3 months ( p = 0.001 )，to 350 土 74 ^moLO. at 6 months ( p 二 
0.001 )，and to 341.22 土 76 at 21 months ( p < 0.001 ) as shown in Tables 3.5a 
and 3.5b and Figure 3.1. 
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3J,L3 Plasma Lipid Concentrations 
The fasting plasma triglyceride concentration decreased significantly in 
the Insulin Group from 1.57 x / - 1.83 at baseline to 1.18 xi— 1.84 mmol/L at 3-
months ( p = 0.001 ) and to 1.21 x h 1.71 nrnioyL at 6-months ( p = 0.001 ). 
However by 21-months, the value had risen to 1.41 x/— 1.68 mmoVL which was 
not significantly different from baseline. 
In the Combination Group the range of values was wide. A fall in 
triglyceride concentration was also observed at 3 and 6 months with a rise back 
towards baseline values at 21 months. However these changes in the 
Combination Group failed to reach statistical significance. ( Tables 3.5a & 3.5b ) 
There is a significant rise ofHDL-cholesterol concentration, ( p <0.05 ) 
found at 21-months when compared to baseline in the Insulin Group although no 
other significant changes were observed in total cholesterol, triglyceride, and 
calculated LDL- cholesterol either within the group or between the groups. 
At 51-months, the mean triglyceride concentration was lower in the 
combination group ( 1.13 x / - 1.73 )，compared to ( 2.03 x / - 1.86 ) in the Insulin 
Group ( p < 0.05 ). No significant differences were found at any time point 
within-groups or between groups for total cholesterol, HDL- cholesterol, or 
LDL- cholesterol at this time. These lacks of significant may reflect the small 
sample numbers and short duration of the study. 
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3.3,2 Ginical Determinants 
3,3.2,1 Blood Pressure Measurements 
In the Combination Group, the mean systolic blood pressure at 21-
months was 143 土 32 mmHg ( NS )’ and mean diastolic blood pressure was 74 土 
11 mmHg. The mean systolic blood pressure at 51-months was 140 土 20 mmHg 
(NS )，and mean diastolic blood pressure was 73± 12 mmHg. These values were 
not significantly different from baseline values measured prior to recruitment. 
In the Insulin Group, the mean systolic blood pressure at 21-months was 
132 土 16 mmHg ( NS )，and mean diastolic blood pressure was 78 土 10 mmHg. 
The mean systolic blood pressure at 51-months was 145 土 23 mmHg ( p < 0.05 
)，and mean diastolic blood pressure was 77 土 9 mmHg. Again these values were 
not significantly different when compared to pre-recruitment values, with the 
exception of the mean systolic value at 51 months which was higher ( p < 0.05 ) 
The percentage of patients on anti-hypertensive drugs increased 
respectively to 30 and 33% at 21- and 51- months in the Combination Group and 
to 30 and 58% at 21- and 51-months in the Insulin Group as compared to the 15 
and 21% before recruitment. 
At baseline, 18% ( #9/51 ) of patients were on anti-hypertensive 
treatment and both groups are similar. However, at the end of the 51-month 
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• 
evaluation period, A significant increase in the proportion of patients requiring 
anti-hypertensive drugs had occured ( p = 0.003, ^ = 7.70 ) and there were 45% 
(#23/51) requiring anti-hypertensive treatment. 
At the 51-month evaluation, 33% ( #9/27 ) in the Combination Group 
and 58% ( #14/24 ) of patients in the Insulin Group were on anti-hypertensive 
drugs.(p = 0.065,x^=2.28) 
Although blood pressure values at 51-month evaluation were similar 
between the two groups, more patients in the Insulin Group needed anti-
hypertensive drugs compared to the Combination Group with the difference just 
failed to reach statistical significance. These findings suggest an association 
between the higher dose used in the Insulin Group and the increased use of anti-
hypertensive drugs. 
3,3.2.2 Body Weisht Evaluations 
Both groups showed a mean increase in body weight following the 
introduction of insulin therapy. The significant differences of weight gain are 
shown in Table 3.6 and Figure 3.2 shows the different significance when 
compared the Combination and Insulin Group at 3, 6，and 21-months and Figure 
3.3 showing the exact data of individual differences of body weight when 
















































































































































































































































































































































Fimre3.2 : Conwarison 0fwei2ht sain in patients recemns either 
combination or insulin therapy (Mean + SEM) 
+ P = ft 05 between the groupSy 
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Fisure 3.3: 
Chanses in bodv wei2ht between the combination and 
insulin srouvs at 3 and 6 months, (mean 土 SD} 
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For the Combination Group, the mean weight gain was 1.6 土 1.8 kg ( 
range - 1.6 - 3.8 ) at 3 months ； 2.1 土 2.5 kg ( range - 3.1 - 5.8 ) at 6 months ( 
both P < 0.001 vs baseline ); 2.1 土 2.6 kg ( range - 2.0 - 8.2 ) at 21-months ( 
both P < 0.001 vs baseline ) and 3.97 土 3.5 kg ( range -2.1 - 13.4 ) at 51-
months. 
For the Insulin Group, the mean weight gain was 3.6 土 4.3 ( range - 8.1 -
10.9 ) at 3 months; 5.1 土 4.1 kg ( range - 4.9 - 12.0 ) at 6 months ( both P < 
0.001 vs baseline ); 5.6 土 5.1 kg ( range - 7.3 - 12.6 ) at 21-months ( P < 0.001 
vs baseline ) and 8.2 土 6.4 ( range -3.1 - 23.3 ) at 51-months ( p < 0.001 vs 
baseline ). 
The increment of weight gain was consistently higher in the Insulin 
Group when compared with the Combination Group ( P < 0.05 at 3 months, P < 
0.01 at 6 months, P < 0.01 at 21 months and p <0.05 at 51-months ). Obesity ( 
using a definition o f B M I > 27 k g W for men and > 25 kg/m^ for women ) was 
present in 30% of the Combination Group and in 27% of the Insulin Group at 
baseline. It increased to 33% and 42% at 3-months; 37% and 50% at 6-months; 
40% and 48% at 21-months; and continued to increase to 50% and 67% at the 
period of 51 months in the Combination and Insulin Groups respectively. When 
changes in body weight between baseline and 21 months are correlated with 
changes in glycaemic control and with insulin dose requirements in each group, 
some significant correlation are observed. In the Combination Group, there is no 
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correlation between change in body weight and any index of glycaemic control; 
whereas in the Insulin Group, an inverse correlation is observed between 
fructosamine and body weight ( r = - 0.49, p < 0.02 ) and between HbAic and 
body weight ( r = - 0.56, p < 0.05 )，although not between FPG and body 
weight. There was no significant within-group correlation seen between weight 
changes and insuUn dose requirement in either group. 
3.3.3 Insulin Types Used 
All of the 27 patients in the Combination Group and 25 patients in the 
Insulin Group used Protaphane Insulin twice daily. Only one patient in the 
Insulin Group used Actraphane Insulin twice daily. 
3.3.4 Insulin Dosase Requirements 
Despite similar improvements of glycaemic control, the insulin 
requirements for the two groups were very different and are summarized in 
Table3.7. 
At the end of 3-months, the Combination Group was receiving a mean 
dose of 14.5 土 7 U/day of insulin, whereas the Insulin Group was receiving a 
mean of 57.6 土 15.1 U/day ( p < 0.001 ). Similar findings were observed at 6-
months ( 15.0 土 6.6 vs 57.2 土 15.4 U/day) ( p < 0.001 ) and at 21 months ( 16.4 




















































































































































































































































































substantially less insuUn ( approximately 25% ) compared to the Insulin Group 
despite similar degrees of improvement in glycaemic control in both groups. This 
difference was maintained at 21 months. On review at 51-months, the dose 
requirements for both groups had risen, more so in the Combination Group, but 
a large and significant difference was maintained 
3.3.5 Subjective WelUBein2: Acceptability Of Insulin Iniection 
The Visual Analogue Scale ( VAS ) scores are summarized in Tables 
3.8a + 3.8b. Following the introduction of insulin, both groups reported 
significant improvement of quality of life compared to baseline ( Figure 3.4 ). 
This was present by 3 months and was maintained at 6 months and 21 months ( p 
< 0.05 at 3 and 6-months, p < 0.005 at 21-months for the Combination Group, 
and for the Insulin Group ( p < 0.005 at 3 months and 6 months and p < 0.05 at 
21-months ). Both groups noted improvements to a similar degree and no 
differences between the groups were observed. Sense of well-being after insulin 
was not assessed at baseline but again the values recorded after the introduction 
of insulin were not significantly different between the two groups. 
Both groups found insulin injections less painful and troublesome than 
they had anticipated when asked to make a predicted assessment at baseline. A 
significant difference was found between expected injection pain and injection 
























































































































































































































































































































































































































































































































































































































































































































































































Fi2ure 3.4 : 
VisualAnalo2ue Scale ( VAS) scores for aualitv of life 
between the combination and insulin sroups 
(mean±SD) 
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problems at 3 and 6 months in both groups This is also shown in Tables 3.8a’ 
3.8b and compared in Figures 3.5 and 3.6. The actual recorded injection 
problems were less severe than had been anticipated at baseline. 
In the Combination Group, the mean value for injection pain was 74.6 土 
18.5 at 3 months, 80.6 土 17.0 at 6 months ( both p < 0.001 vs baseline ) and the 
mean value for injection pain was 74.8 土 19.5°/^ at 21-months ( NS vs baseline ) 
In the Insulin Group, the mean value for injection pain was 69.6 土 19.3 
at 3 months ( p < 0.05 vs baseline ); 76.2 土 17.6 at 6 months ( p < 0.01 vs 
baseline ) and 71.5 土 24.2。/o at 21-months ( p < 0.05 vs baseline ) Significant 
changes were also found in recorded troublesomeness of injections within the 
groups during the 3 and 6 months evaluation in both groups. For the 
Combination Group, the mean score was 68.2 土 20.8 ( p < 0.05 vs baseline ) at 
3-months, 76.1 土 23.6 ( p< 0.005 vs baseline ) at 6-months, and 69.6 土 29.8 at ( 
NS ) at 21-months. For the Insulin Group, the mean score was 65.8 土 28.6 ( p < 
0.05 vs baseline ) at 3-months, 69.4 土 28.5 ( p< 0.005 vs baseline ) at 6-months, 
and 61.76 土 39.3 at ( NS ) at 21-months. These results are compared in Figure 
3.3 and3.4 
Well being and quality of life improved significantly in both groups. Most 
patients felt better after insulin, and there was no significant difference between 
the groups. The majority of patients (significantly more in the Combination 
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Fisure 3.5: 
Comparison of VisualAnal02ue Scale ( VAS) scores for 
insulin injection vain at 3. 6�and21-montks between 
the Combination andInsulin Groups ( mean ± SD ) 
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Fi2ure3.6: 
Comparison of Visual Anal02ue Scale ( VAS) scores for 
insulin iniection problem at 3. 6. and 21-months between 
the Combination andInsulin Groups ( mean 土 SD ) 
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Group) wanted to continue insulin therapy beyond six months ( 89% ) for 
Combination Group vs 76% for Insulin Group ( p<0.001) and this was 
maintained at 21-months, when 83% expressed a desire to continue insulin 
irrespective of the treatment group. 
3.3.6 Hvposlvcaemic Events 
The mean number of attacks was 1.4 per patient in the Combination 
Group and 1.0 per patient in the Insulin Group. There were no significant 
differences between the groups. All attacks were mild. Only minor adjustments 
to insulin dosage and/or redistribution of diet were required to alleviate 
hypoglycaemia. Treatment continued after adjustment of food intake by the 
dietitian without further adverse affects. Definitions of adverse events are shown 
in appendix III. No severe hypoglycaemic attacks, as defined by need for outside 
assistance to reverse the attack, were recorded in either group. 
3.3.7 Subsequent Study Discontinuation 
At the end of the first 3-months period, two out of 55 subjects 
discontinued.the study. One subject in the Combination Group defaulted and 
contact was lost. The other subject in the Insulin Group was put into jail soon 
after the commencement of insulin. Data from both subjects were removed from 
the analysis. 
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The remaining 53 subjects subsequently completed the main 6-months 
period of the study. At the longer term assessment carried out after 21-months, 5 
other subjects had discontinued and 48 remained. 23 patients continued in the 
Combination Group and 25 in the Insulin Group. In the Combination Group, 4 
had switched to full insulin substitution as a result of poor glycaemic control. 
The identifiable reasons were : intercurrent cellulitus in one, development of 
tuberculosis in another，and failure of glycaemic control in the remaining two. 
One subject in the Insulin Group discontinued insulin herself, against medical 
advice. By the time of the 51-months evaluation, 9 more subjects had 
discontinued which left 39 subjects for re-evaluation. In the Combination Group, 
5 subjects discontinued due to combination failure in three cases, renal failure in 
one，and a decision to take alternative treatment from a general practitioner in 
the other. In the Insulin Group, 4 had been recruited for other trials and their 
data was excluded from the analysis. 
3.3.8 Responders versus No Resyonders 
Responders were defined as patients who achieved HbAicvalues less than 
8.9% with, ah arbitrary definition using upper limit 土 2 SD as cut off point. ( See 
Table 3.9 ). Figures 3.7a and 3.7b indicate the individual data for HbAic control 
between the groups. A few patients show marked increases in HbAic suggesting 
possible explanation of non-compliance. However, the overall conclusion 











































































































































































































































































Fimre 3.7a : 
Effect on HbAj^ after 6-months of insulin treatment 
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Effect on HbAj^ after 6-months of insulin treatment 
in the Insulin Group 
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^mol/L and HbAic > 8.9% at 6 and 21 mOnths as indicators of non-response, we 
found that seven patients in each group failed to respond at 6 months. At 21-
months 13 patients in the Combination Group and 7 patients in the Insulin Group 
failed to meet these criteria. Failure of response did not correlate, in either 
group, with any ofthe baseline parameters examined, namely age, weight, BMI, 
duration of diabetes, indices of glycaemic control, lipids ( total and HDL 
cholesterol and triglyceride )，types of OHA therapy ( sulphonylurea alone or 
combined with metformin ), and fasting and stimulated C-peptide concentration. 
Thus, no baseline characteristics examined gave any clue as to future failure to 




4,1 SUMMARY OF THE RESULTS 
The efficacy, side efFect, and quality ofl i fe were evaluated in 53 M D D M 
Chinese patients with confirmed oral hypoglycaemic agent failure over a mean 
period of 3, 6，and 21-months ( range 18 - 26 months with a mean period of 
21.1 土 2.0 ) for Combination Therapy vs Insulin Therapy with further later 
evaluation at a mean 51-months duration ( range 24.8 - 67.6 months, mean 50.5 
土 8.2 months). 
The mean duration of 9.0 土 4.9 D M years of the subjects shown in this 
study ( Table 3.1 ) is consistent with the many literature reports in the 
development of secondary failure and the need for exogenous insulin therapy 
within 5-10 years after the initial response to oral hypoglycaemic agents. (Yki-
Jarvinen et al., 1992) 
A conclusion can be made that OHA - Insulin Combination Therapy for 
secondary drug failure remains an effective and well tolerated treatment in a 
mean 51-month follow-up duration and may be considered as a realistic 
alternative to full insulin replacement in most patients, at least for this 
intermediate period of time. 
The effectiveness of Combination Therapy is shown in the significant 
improvement of three parameters of glycaemic control ( FPG, HbAic, and 
fructosamine ) during the different time periods examined ( Figure 3.1 ). The 
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improvement was most noticeable at the 3-month period but continued and was 
maintained at 6, 21, and 51 -months. 
Nineteen subjects continued with the OHA + insulin combination regimen 
out of the original 27 severe ( FPG's > 13 mmoLT., HbAic > 10% ) secondary 
oral hypoglycaemic agent failure subjects who were randomized into the 
Combination Group. Combination Therapy may be more effective and most 
useful i f introduced to patients at an earlier stage of secondary OHA failure, for 
example when HbAic values consistently exceed 8%. The results of the Diabetes 
Control and Complications Trial (DCCT, 1993) suggest that the risk of long-
term diabetic microvascular complications accelerates strongly at HbAic values 
exceeding 8%, providing clinical justification for this approach. 
The sample population for this study is representative of the local 
diabetic population and bias was reduced by randomization. Similarities of 
baseline characteristics of subjects between the Combination and Insulin Groups 
(Table 3.3 ) also indicates that the comparisons made between the groups 
following treatment are valid. 
The most important finding is that although glycaemic control improved 
to a similar degree in both groups, the Combination Group required a much 
lower insulin dose to achieve the same degree of glycaemic control and also 
gained significantly less weight. This is consistent with many previous 
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comparison studies between combination therapy and mono insulin therapy 
either by parallel or crossover design methods as shown in Tables 4.1，4.2a, 
4.2b’ 4.2c.and4.3. 
The insulin dose in the Combination Group was consistently 
approximately 40 U/day lower than in the Insulin Group throughout the study at 
3，6，21 and 51 months ( Table 3.7 ) These findings are consistent with early 
findings as in the 1950 and also recent literature as summarized in Table 4.1 by 
Bailey and Mezitis 1990 Kinsell et al were the first to confirm the "insulin 
sparing" effect of sulfonylureas with a reduction of insulin dose by 50%. ( Table 
4.1 ). Several recent studies in the 1980's also demonstrated the reduction of 
requirement for insulin when combined with sulphonylurea by using a parallel or 
crossover design with similar methodology to compare combination therapy with 
insulin therapy as shown and summarized in Tables 4.2a, 4.2b，42c. 
The larger difference of insulin requirement, despite equally good 
glycaemic control, between the groups in this study compared to others probably 
reflects the carefully supervised, step-wise increase of insulin dosage in 
attempting to achieve euglycaemia within an 8-week stabilization. The carefiil, 
supervised step-wise increase of insulin to achieve euglycaemia with an 8-week 
stabilization period should have alleviated any intrinsic bias and can explain the 
magnitude of the difference of insulin requirement between the groups, 
particularly since the ultimate degree of glycaemic control achieved was similar. 
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Table4.1: 
Different Trial Desians of Combinaiton Theraov in Non-lnsuUn Dependent Diabetes Mellitus 
Results Study 
Investigators n Sulohonvlrea Insulin Dose Duration 
(decreased) (week) 
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Stnimann, 1957 '[ 5 sulphpn^ui^ 37% notd^ned 
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.¾/!¾^^^.¾.>¾¾. '97 giy'buride 
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::ii]^《fjj—|j:+:r:—; 1982 : : 19 ^hfit)Sl^fpjj:ffi ^% noid^neid 
Bieger eiai, 19B4 40 giyburide 20m^day decreased 6 
placebo 
Groiop ei aY, 1984 13 giyburide none 20 
Insulin 
Fmo *Osd| 1985 9 Gtybu'ride 16 
Insulin 
Kyjlf^pn^^ 
‘Naiinih ef^ 1985 :: 39 gjj^jl^f^^^^g 3 




C^mioeiai, 1987 10 Glipizide 30 nig/d 6 
non-obese ( ^J^|n 20% of ideal wf^ 
Hoiman ei'sU', 'i987 15 ij.6Jj&.(^i:.iiicK^i^'^.i^“il^i 
(^解冲照9"终 
Lii“d“l^“““““ ei ai, 1987 79 gi^“"^pij^fi‘“9 decres^ed 56 
‘'Re/ch et af. 'l987 20 Glybu'ride '4om^'d 6 
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:Bachmaiin eta(, 1988:::: :::. 37 otowe Gfybunde ::: : '^% 24 
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Although plasma free insulin concentrations were not measured in this 
study, data from another similar study (Yki-Jarvinen et al, 1992) indicated a 
much higher diumal level in the insulin treatment group when compared to the 
Combination Group who also received a much smaller dose of exogenous 
insulin. Yki-Jarvinen et al had used insulin 5 different ways and compared their 
effectiveness and concluded an evening injection with day time oral 
hypoglycaemic agents is most advantages and far more a superior regimen for 
secondary failures (Yki-Jarvinen et al., 1992). Clearly Combination Therapy 
might be preferred if the possible atherogenic effects of peripheral 
hyperinsulinaemia are considered and appropriate glycaemic control can be 
obtained. (Stout, 1979; Stolar, 1988 ) 
The potential side effect of hypoglycaemia was not a major problem in 
this study group There were no differences in the number of hypoglycaemic 
attacks seen in the two groups and no subjects experienced any severe episode of 
hypoglycaemia. However it should be remembered that the close supervision of 
the patients under the study conditions may have reduced this risk. Patient 
contact was frequent through the use of telephones and detailed explanation of 
the importance of adherence to diet, exercise and injections was provided ( 
Chapter 2.3.2). 
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4.2 ACUTE & LONG TERMEFFECTS OF COMBINATION THERAPY 
It is now generally accepted that N K ) D M patients are characterized by 
both insulin resistance and insulin deficiency although the relative contribution 
from each may vary between patients (Kolterman, Gray, Griffin, Burstein, Insel, 
Scarlett & Olefsky, 1981; Davidson, 1986; Haffiier et al,, 1996) Sulphonylurea 
drugs act to improve diabetic control predominantly by enhancing pancreatic 
insulin secretion and also to a lesser extent by decreasing peripheral insulin 
resistance perhaps secondary to improvement in glycaemia (Gerich, 1989). As 
NK)DM advances, secondary failure of OHA therapy develops as a consequence 
of many potential factors which may include progressive loss of jff-cell function 
or deterioration of insulin resistance caused by persistent hyperglycaemia and 
possible development of drug resistance. Causes of secondary failure are 
summarized in Table 1.7. (Groop & Tolppanen，1984; Olefsky, 1985; Groop et 
al., 1989) This leads to a need for exogenous insulin therapy. Conceptually, 
combined therapy that allows continuation of sulphonylureas and possibly 
metformin seems the logical next step. Metformin is often used in combination 
with sulphonylurea and is particularly useful in overweight patients. The effect of 
metformin as compared to sulphonylurea in contributing to the insulin dose 
sparing effect of Combination Therapy has not been directly examined in this 
study. A further study is in progress in our Unit to directly address this point and 
the results to date do suggest that metformin does add further to the insulin 
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V 
sparing effect ofCombination Therapy when compared to Sulphonylurea alone ( 
data not shown ) 
Over the last decade, numerous trials using combination therapy have 
been conducted, but available results continue to be conflicting and firm 
conclusions are difficult to draw. O^eters & Davidson, 1991; Pugh et al., 1992) 
Early studies mainly reported the addition of OHA to existing insulin 
therapy as shown in the work of Kinsell et al ( 1956 )’ who demonstrated 
effectiveness only in mild D M and not severe cases; Stratmann ( 1957 ) showed 
37% reduction ofinsulin dose in 5 very poorly controlled D M subjects by adding 
sulphonylurea. Volk and Lazarus ( 1959 ) reported similar findings. 
Knick et al ( 1970 ) studied a homogenous and large population of 171 
subjects, using a single sulphonylurea and biguanide, but the length of 
observation, inclusion and exclusion criteria were uncleared. 
In 1982, Hamelbeck et al conducted the first randomized, double-blind 
placebo-controlled trial in M D D M with similar age, weight, duration o f D M and 
glycaemic control, and resulted increases in both basal and meal-stimulated c-
peptide levels with glibenclamide compared to placebo. 
Traumann ( 1982 ) conducted a crossover study which resulted in 
decreased insulin dose requirements, improvement in fasting and 2 hour post 
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prandial blood glucose concentration in 19 subjects. Again, classification o f D M 
subjects were unclear and the duration ofinsulin treatment was not specified 
Kyllastinen and Groop ( 1985 ) also shown Combination Therapy's 
effectiveness, but due to a lack of exclusion criteria his subjects were poorly 
maintained (Bailey & Mezitis 1990). 
Analysis by Lebovitz and Pasmantier of the results of 17 different studies 
conducted in the nineteen eighties ( 1983 - 1989 ) emphasized this controversy 
as summarized in Tables 4.2a, 4.2b, 4.2c. Many reasons have been put forward 
to explain these conflicting results. These include uncontrolled trials, studies of 
relatively short duration, intrinsic differences between the study population, 
inadequate sample sizes which failed to show statistical significance. The less 
logical design of adding a sulphonylurea to a large dose of existing insulin, 
different duration of disease and different initial responses to sulphonylureas 
which might contribute to different treatment responses. Treatment regimens 
themselves may vary enough to cause conflicting results (e.g. adding a small 
dose of insulin to a sulphonylurea vs adding a sulphonylurea to a large dose of 
insulin ).(Lebovitz & Pasmantier，1990 ).(Pugh et al., 1992) 
In the present study, apparent OHA failure due to patient-related factors, 
such as diet failure, poor compliance, lack of exercise, or intercurrent illness, 
were carefully excluded by an initial screening process. Such factors appeared to 
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exist in 25 - 30% of the initial patients screened, in agreement with earlier 
studies. (Sonksen, Lowry, Perkins & Lim，1984; Groop, PeIkonen, Koskimies, 
Bottazzo & Doniach，1986) The two groups of patients finally recruited were 
comparable both at the time of establishing the clinical indication for insulin 
therapy and after successful stabilization on insulin. The results indicate that both 
regimens are equally effective in improving glycaemic control, up to a mean 21-
months duration period and continued to have good glycaemic control even 
looking at it during the mean 51-months stage. However, OHA combined with 
low-dose insulin therapy may be preferred i f the possibly detrimental effects of 
weight gain and hyperinsulinaemia are considered. 
Glycaemic control as defined by FPG, HbAic and fructosamine improved 
significantly and equally in both groups. The slightly better improvement of 
fructosamine at 3 months for the Insulin Group may indicate a more rapid effect 
of full insulin substitution. Otherwise overall improvement rates were similar for 
both groups. Although substantial improvement in glycaemic control was 
observed, neither group achieved normal glycaemic control as a whole, although 
HbAic values, were normalized in some individuals in both groups. This may be 
partly attributable to the study design, and the use of a protocol which set an 
artificial upper limit to the insulin doses used. However while this may have 
attenuated the improvement in control in some subjects, it does not negate the 
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significant differences in the insulin doses required to achieve similar 
improvements in control in the two groups. 
The fasting and stimulated C-peptide responses in the Insulin Group were 
marginally lower than those in the Combination Group at baseline ( p < 0.06 ) as 
shown in Table 3.3. Thus, it is possible that the Insulin Group is more insulin 
deficient. However, this is unlikely to explain the large difference in insulin 
requirement to produce similar glycaemic control. The mean 土 SD BMI of our, 
predominantly female, study group is 24.2 土 4.3 kg/m^ ( Table 3.1 ) and 
represents a typical cross section of our diabetic population (Chan, Cheung, 
Swaminathan, Nicholls & Cockram, 1993). Compared with a typical U. S. 
NK)DM population of OHA failures with similar age and duration of diabetes 
(Groop et al, 1989), our study population is more lean and therefore possibly 
less insulin resistant. This could again explain the relatively low insulin dose 
needed for good control. 
One side effect of insulin therapy is weight gain. In this study, both 
treatment groups gained weight considerably although with much variation 
between individuals. This could partly reflect improvement in glycaemic control 
and overall health. However, despite similar glycaemic control, the Insulin Group 
gained approximately twice as much weight as the Combination Group at both 
3-, 6-, and 21-months, and this difference was maintained at 51-months ( Table 
3.6 ). Half of the Insulin Group, nearly doubling the number at baseline, had a 
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rise in B M I to obesity levels, while only about one third of the Combination 
Group reached obese levels o f B M I at 6 months. This reflects a higher degree of 
peripheral hyperinsulinemia in the Insulin Group with the consequences of 
accelerated lipogenesis as well as possible stimulation of appetite (Booth & 
Brookover, 1968) Again, this excessive weight gain and hyperinsulinaemia could 
theoretically have a deleterious effect on blood pressure and macroangiopathy 
(Ferrannini & Defronzo, 1989; Randeree, Omar, Motala & Seedat, 1992) and 
may weight in favor of combination therapy rather than full substitution therapy 
as long as the improved glycaemic control can be maintained. 
In accordance with previous reports concerning insulin therapy in 
N K ) D M (Taskinen, Kuusi, Helve, Nikkila & Yki-Jarvinen，1988; Lindstrom, 
Amquist & Olsson，1990) we observed a significant fall in plasma triglyceride 
concentration (by 13-22% ) in the Insulin Group only at 6-months but not at 21-
months. Total and HDL cholesterol did not change in either group, and the 
significance of these changes in terms of future atherogenesis remain uncertain. 
Both insulin treatment regimens were well tolerated, and hypoglycaemic 
attacks were* mild and infrequent in both groups. Most patients reported 
improved general well-being after insulin treatment, and there was no difference 
between the groups. However, when acceptability of injections was examined, 
there was a significant difference in favor of the Combination Group particular in 
terms of desire to continue the treatment beyond 6 months and also at 21-
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months. With a single bedtime insulin injection combined with their existing oral 
therapy, the patients may be better motivated to accept insulin therapy in the 
initial stages of secondary failure. This treatment regimen is also socially more 
acceptable to patients, especially for those depending on relatives to give the 
daily insulin injection (s). 
C-peptide measurements may help to predict the response to insulin 
(Peacock & Tattersall, 1984) However in this study, attempts to predict the 
magnitude of response from baseline parameters such as C-peptide failed and 
failure to respond appeared to occur with equal frequency in both groups 
irrespective of the baseline assessment of / -ce l l function. This contrasts with 
other studies that have indicated that degree of obesity (Gutniak et al., 1987; 
Lewitt, Yu, Rennie, Carter, Marel, Yue & Hooper，1989), degree of initial 
hyperglycaemia (Longnecker, Eisenhaus, Leiman, Owen & Boden, 1986; Lewitt 
et aL, 1989)，fasting C>peptide concentration (Longnecker et aL, 1986; Lewitt 
et al., 1989) and triglyceride concentration (Sane, Helve, Yki-Jarvinen & 
Taskinen, 1992) may help to predict the response to combination therapy. The 
upper constraints of the insulin dose, set by the limits of the protocol, may 
however have contributed in this study, to the lack of correlation of the response 
to the baseline parameters. 
Current evidence, as strongly supported by the results of this study, 
would appear to indicate that it is reasonable to try combination therapy initially 
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in all patients with OHA failure. The best practical indicator of the response is 
the insulin dose required to achieve good glycaemic control. Patients requiring 
more than 0.5 U-kg'* • day"^  can probably be transferred to full substitution with 
insulin (Bachmann et a/.’ 1988). This can be done either immediately, or at a 
later stage i f the dosage requirement rises with time. This process has the 
additional advantage, in many patients, of making the transition to insulin more 
acceptable, the psychological factor of switching to injection therapy being 
minimized, because the gradual introduction of insulin may be preferred. This 
approach may also be more closely adapted to the natural history of the disease 
and gradual decline in insulin secretory capacity. Careful supervision is however 
required so that potential failure of combination therapy in the fiiture can be 
diagnosed in a similar manner to the earlier failure of OHA alone and corrected 
by switching to full substitution with insulin. Assuming that these precautions are 
taken, it seems reasonable to recommend that all patients with secondary drug 
failure be considered for combination therapy. We remain unconvinced that 
responders and non-responders can be predetermined accurately by generally or 
routinely available methods. Also the psychological impact involved in switching 
to injection therapy may be minimized, and this facilitates the procedure for 
initiating insulin therapy in patients, who as a group, are generally reluctant to 
make this change. 
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Based on this study, the recommended action for management guidelines 
can be summarized as follows. However, it should be pointed out that some 
patients are unable to tolerate metformin in which case insulin can be added 
directly to sulphonylurea. 
Sulphonylurea or Metformin 
�r 
Sulphonylurea + Metformin 
+ 
Sulphonylurea + Metformin + Insulin 
^ 
Insulin 
Further studies are required to clarify the details of optimal regimes, 
including the use of different insulin preparations and regimes. The optimal doses 
of sulphonylurea also need to be clarified, as does the potential role of 
metformin. We have subsequently move on to examine these topics further. The 
data are not shown in this thesis but summaries of the results have been included 
for reference at the rear of this thesis. 
Twenty to thirty years ago Lestradet et al ( 1960 ); Fergusson et al ( 
1962 ) and Pirart ( 1971 ) investigated possible synergy of metformin with 
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insulin therapy. Only in the last 5-10 years has it been clarified that metformin 
can act in the presence of insuUn ( either exogenous or endogenous ) in 
facilitating its effects, ^^ein, 1991) 
The prospect of successful treatment depends upon many other factors as 
we need further information on genetic susceptibility and environmental 
influences. 
In therapeutic terms, it seems more cost-effective to use Combination 
Therapy in the management of secondary OHA failure. Perhaps Combination 
Therapy could be introduced at an earlier stage with HbAic > 8% or even at the 
initial diagnosis o fNK)DM in selected patients. 
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APPENDIX 
AppendixI: CHINESE CONSENT FORM 
香港中文大學 




Prince ofWales Hospital 
硏究醫師：周振中醫生/郭克倫敎授 
bivestigators: Dr. Chun Chung Chow, Professor CIive S. Cockram 
接受「胰島素治療」同意書 
Acceptance ofbKulin Treatment 
病人號碼P a t i e n t # : 香港身份證號碼HKID: 
本人 現居 




I understand and agreed to participate in the study of “ Comparison of OHA plus 
Insulin or Switching to Insulin Therapy Alone ”. I also understand that I can discontinue 
the study at anytime. 
Patient's signature 病人簽名: 





EXPLANATION OF THE STUDY TO PATIENTS ATRECRUITMENT 
In order to standardize the approach to the patient somewhat, an 
explanation along the line of what's below were given to each patient at 
recruitment : 
“ The diabetes you have was at one time controllable by oral Tablets 
alone. Your present blood sugar levels are still high，and we cannot increase 
any more in the number of Tablets due to your ability to metabolize its 
toxicity. Therefore，insulin is recommended，the technique is very simple and 
I shall be around to help for at least half a year with any problems or 
difficulties which you might encounter. 
Since we don，t know whether ifa complete switch to insulin is the best 
management for diabetics, the plan is to try some patients on a complete 
switch to insulin and some continue on the maximum dose and add night 
time insulin to the present maximum OHA. You cannot choose one treatment 
over another and a consent must be signed. Either method，better control will 
benefit you in many ways，including preventing problems in later years to 
your eyes, your nerves andyour kidneys,，， 
• 
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Appendix III Definitions ofAverse Events 
An adverse event: is any undesirable event occurring to a subject during the trial, 
whether or not considered related to the investigational product. 
A serious adverse event: is any experience that is fatal or life-threatening, 
is permanently disabling, requires impatient hospitalizations 
or prolongs hospitalization, is a cancer or overdose. 
Severity: 
MUd: Transient symptoms, no interference with patient performance, acceptable 
Moderate: Marked symptoms, moderate interference with patient performance, 
but still acceptable 
Severe: Considerable interference with patients performance, but still acceptable. 
ReUitionshw to Study Drue: 
Probable: Good reasons and sufficient documentation 
to assume a causal relationship 
Possibh: A causal relationship is likely and cannot be excluded 
Unlikely : The event is most likely related to an etiology 
other than the study treatment 
Unknown : Causality is not assessable, 
e.g. because of insufficient evidence, 
conflicting data or poor documentation 
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AppendixlV Page 1: Demosravhic data to be filled in at Recruitment 
1 Personal ParticuUirs: Date:_ 
Name •• Phone: 
D.O.B •• Sex/Age / 
HKid: Miulical#: 
2 History: 
Age diagnosed DM: Duration of DM: 
Age started OHA : Duration ofOHA : 
Used insuUn before ？ Yes /No • How many occasions: 
When was insuUn used: 
Why was insuUn stopped •• 
3 Details ofPresent OHA Treatment: 
Sulphonybirea •• mg / day: 
Metformin used: mg / day : 
Other medications: 
Dietary advice tried: Yes/No 
Effort in compUance: 200d / some / Uttle / none 
4 Diaenosis of Secondary OHA Faibire: 
Fastim PUisma GUicose (FPG) > 7.8 mmoLZ or 
Random PUisma GUicose ( RPG ) or 2 hour pp > 11.1 mmol/L 
FPG : Random PG: 2 hour pp: 
Urinary sujgar: Ketones •• 
Nocturia: Yes/No , times 
5 Consent to use insuUn after expUination ？ 
patient signed: Yes/No Interviewer signed: Yes/No 
6 Does concurrent disease prevent participation in studv ？ 
Ifyes, diagnosis : 
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Appendix V Pase 1 continued. 
List of concurrent conditions preventine participation in this studv 
Yes No 
Diabetes already usins insulin 
TvpeIDiabetes 
Unstable Diabetes: 
Hvv02lvcemia or Ketoacidosis 
Ischemic Heart Disease: 
Aneina or previous Myocardial Infarction 
Peripheral Vascular Disease 
Known Proliferative Retinopathy 




* creatinine >150 |imol/L 
** akoholconsumption > 50gm/day 
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Appendix VI Paee 2: To be completed durim VlsU 2 
Run-In Period: Biochemistry evaluation at baseline 
Name: Randomization #: 
BaseUne Measurements Date: 
Weight: kg Height: m BMI: kg/m2 
Biochemistry: 
FPG: mmol/L ； Fructosamine: fimol/L; HbAlc •• % 
C-peptide: fasting ng/ml SHmuUaed: ng/ml 
Total ChoUsterol: mmol/L 
Triglyceride: mmol/L 
HDL ChoUsterol: mmol/L 
LDL Cholesterol: mmol/L 
Does not need to repeat ifnormal within past vear : 
CompUte BU)od Count Liver Function Test 
Renal Function Tests 
117 
Appendix VII Paee 3: WeU beine evahiotions at BaseUne before InsuUn Treatment 
Using the Visual Anahgue Scale ( VAS) 
The range of 0 -100 wUh 100 being the maximum 
Name: Randomization #: 
WeU'beine evabioHon Date •• 
Degree of independence : 
can manage tdone has a job married needs a nurse 
needs help at home does not work Uves ahne doesn *t Uve ahne 
Has any major change occurred in your tife during the past two weeks, 
e.g. ckangeofjob, death in the family, serious iUness? 
PUase specify: 
score 
1. How wiU do you sUep at night? 
0 - often awaken and found it difficuU to faU asUep again 
100 - sleep deeply aU night hng 
2. How do you feel when you wake up in the morning ？ 
0 — don't feel Uke doing anything, rather stay in bed 
100 = feel great and ready to go 
3. How often do you see other people ？ 
0 = never see other people 
100 = see friends and family often 
4. Describe your ucHvUy level during the course of the day. 
0 = don 't do much 
100 - get a ht done 
5. How much time do you spend on leisure activities ？ 
0 — none 
100 = as much as wanted to 
6. Haw do you feel in the evening ？ 
0 = tired and umveUj faUs aUep early 
100 — energetic and weU 
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Appendix VIII Paee 4: To be completed durim Visit 3 
3-Afontks Evaluation 
Name: Randomization U: 
Jnvestisations at end of 3-month treatment Date •• 
OHA : Yes/No Type: mg/day 
InsuUn ( U/ day ) •• AM = Actrapid •• Actraphane: 
Protaphane •• 
PM = Actrapid: Actraphane: 
Protaphane: 
Any urinary ketones during the past three months ？ Yes/No 
Any Hypoglycemic complaints : Yes/No ； Mild /Moderate /Severe: times 
Nocturia : Yes/No times/night on average 
Weight: kg, Height: cm, BMI: kg/m ^  
Biochemistry: 
FPG: mmoUL 2 hour pp : mmol/L 
HbAlc: % Fructosamine: fimol/L 
Urinary sugar : Ketones : 
Total Cholesterol: mmoUL 
Triglyceride : mmoUL 
HDL Cholesterol: mmol/L 
LDL Cholesterol: mmoUL 
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Appendix fX Pa^e 5: Questionnaire Evaiuation at 3-month 
Using the Visual Anahgue Sctde ( VAS) 
The range of 0 - 100 with 100 being the maximum 
Name: Randomization U •• 
Part / : WeU-heine evaUiaHon Date: 
Degree of independence: 
can manage ahne has a job married needs a nurse 
needs help at home does not work Uves alone doesn*tUveahne 
Has any major change occurred in your life during the past two weeks, 
e.g. change ofjob, death in the family, serious illness? 
Please specify: 
score 
L How will do you sleep at night? 
0 = often awaken and found it difficult to fall asleep again 
100 = sleep deeply all night long 
2. How do you feel when you wake up in the morning ？ 
0 = don ,t feel like doing anything, rather stay in bed 
100 = feel great and ready to go 
3. How often do you see other people ？ 
0 = never see other people 
100 - see friends andfamily often 
4. Describeyour activity level during the course of the day. 
0 - don'tdo much 
100 - get a lot done 
5. How much time doyou spend on Uisure activUies ？ 
0 =none 
100 = as much as wanted to 
6. How do you feel in the evening ？ 
0 - tifed and uttwell,faUs aleep early 
100 = energetic and well 
Part II: Deeree of acceptance with insulin injections 
1 0 = it hurts a lot 
100 = U doesn 't hurt a bit 
2 0 = Ws a lot of trouble 
100 = Ws not trouble at aU 
3 0 = don 't feel any better 
100 = feel much better 
4 After having tried insuUn therpy, will you continue to use it? Yes/No 
Ifno, why not? 
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AppendixX Pase 6: To he conwleted during Visit 4 
6-Month Evaluation 
Name: Randomization U: 
Investieations at end of 6-month treatment Date: 
OHA : Yes/No Type: mg/day 
InsuUn ( U/day ) : AM = Actrapid: Actraphane: 
Protaphane: 
PM = Actrapid: Actraphane: 
Protaphane: 
Any urinary ketones during the past three months ？ Yes/No 
Any Hypoglycemic compUiints: Yes/No ； Mild/Moderate/Severe; times 
Nocturia : Yes/No times/night on average 
Weight: kg, Height: cm, BMI: kg/m ^  
Biochemistry: 
FPG: mmoUL 2 hour pp : mmoUL 
HbAlc: % Fructosamine : fimoUL 
Urinary sugar: Ketones: 
Total Cholesterol: mmoUL 
Triglyceride: mmoUL 
HDL Cholesterol: mmoUL 
LDL Cholesterol •• mmoUL 
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AppendixXI Pase 7: Questionnaire Evaiuation at 6-month 
Using the VisualAnalogue Scale ( VAS) 
The range of 0 -100 wUh 100 being the maximum 
Name: Randomization #: 
Part I : WeU-beine evaluation Date: 
Degree of independence: 
can manage alone has a job married needs a nurse 
needs help at home does not work Uves aU>ne doesn 't Uve cdone 
Has any major change occurred in your life during the past two weeks， 
e.g. change ofjob, death in the family, serious ilbtess? 
Please specify: 
score 
L How will do you sleep at night? 
0 - often awaken andfound it difficuU to fall asleep again 
100 - sleep deeply all night long 
2. How do you feel when you wake up in the morning ？ 
0 - don't feel like doing anything, rather stay in bed 
100 = feel great and ready to go 
3. How often do you see other people ？ 
0 = never see other people 
100 = see friends andfamily often 
4. Describe your activity level during the course of the day. 
0 = don't do much 
100 = get a lot done 
5. Haw much time do you spend on leisure activities ？ 
0 =none 
100 = as much as wanted to 
6. Haw doyou feel in the evening ？ 
0 = tired and unwell,falls aleep early 
100 = energetic and weU 
Part II: Deeree of acceptance with insulin injections 
1 0 = U hurts a lot 
100 = U doesn 't hurt a bit 
2 0 = U's a lot oftrouble 
100 = Ws not trouble at all 
3 0 = don't feel any better 
100 = feel much better 
4 After having tried insulin therpy, wiUyou continue to use it? Yes/No 
IfnOf why not? 
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AppendbcXII Page 8: To be conwleted during Visit 5 
18-Month Evaluation 
Name •• Randomization U: 
Investieation at end of 18-month treatment Date: 
OHA : Yes/No Type: mg/day 
InsuUn ( U/day ) : AM = Actrapid •• Actr<q>hane: 
Protaphane ••_ 
PM = Actrapid: Actraphane: 
Protaphane ••_ 
Any urinary ketones during the past three months ？ Yes/No 
Any Hypoglycemic compUunts: Yes/No ； Mild /Moderate/Severe •• times 
Nocturia : Yes/No times/night on average 
Weight: kg, Height •• cnt, BMI: kg/m^ 
Biochemistry: 
FPG: mmol/L 2 hour PP: mmoUL 
HbAlc : � % Fructosamine: ^moUL 
Urinary sugar: Ketones: 
Total Cholesterol: mmoUL; Triglyceride: mmoUL 
HDL Cholesterol: mmoyi; LDL Cholesterol: mmol/L 
Renal/Liver Function Tests: ； Full Blood Count: 
C-peptide :fasting ng/ml, stimulated: ng/ml 
123 
AppendixXIII Paee 9: Questionnaire Ev<Uuation at 18-month 
Using the VlsualAntdogue ScaU ( VAS) 
The range of 0 - 100 with 100 being the maximum 
Name: Randomization U •• 
PartI •• WeU'beine evaluation Date: 
Degree of independence: 
can manage alone has a job married needs a nurse 
needs help at home does not work Uves aU>ne doesn 't Uve ahne 
Has any major change occurred in your Ufe during the past two weeks, 
e.g. change ofjob, death in the family, serious illness? 
Please specify: 
score 
1. How wUl do you sleep at night? 
0 = often awaken andfound it difficuU to fall asleep again 
100 - sleep deeply all night long 
2. How do you feel when you wake up in the morning ？ 
0 = don 't feel like doing anything, rather stay in bed 
100 - feel great and ready to go 
3. Haw often do you see other people ？ 
0 = never see other people 
100 = see friends andfamily often 
4. Describe your activity level during the course of the day. 
0 -don'tdomuch 
100 = get a lot done 
5. How much time do you spend on leisure activities ？ 
0 - none 
100 = as much as wanted to 
6. How do youfeel in the evening ？ 
0 = tirfid and unwell,falls aleep early 
100 - energetic and well 
Part II: Deeree of acceptance with insulin injections 
1 0 =ithurtsalot 
100 = U doesn ,t hurt a hit 
2 0 = it's a lot oftrouble 
100 = U's not trouble at all 
3 0 - don 't feel any better 
100 - feel much better 
4 After having tried insulin therpy, will you continue to use it? Yes/No 
Ifno, why not? 124 
AppendixXry Meter Specifications for Home Glucose Monitorine Machines 
B0ehrin2er Mannheim (BM) Ames 
Technical Soecifwations 
Type: Reflobvc ® S GUicometer GX 
Dimensions: 138 mm 113mm 
Measuring Range: 0.5 - 27.7 mmol/L 1.4 - 22.1 mmol/L 
Measurement Conditions: 
Temperature Range •• 18�- 35 ® C lS ® - 30 ® C 
Power Supply: 6 voU battery 2 non-repUu:eable Uthium batteries 
(IEC4LR44, 4G13 orAS44) wUh a use Ufe oflS,000 readings 
Storage Capacity: 20 Mood gUicose vabies 10 bU>od gbicose vabies 
with time and date average vabie of aU the test resuUs 
and 
can be stored in memory 
Humidity Range •• < 75% < 85% 
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• Phase 2 of a 2-phase trial (a randomised, open and parallel triai, observed in group with metformin withdrawn 
see other poster) 
• Study period of 5 weeks 4.5 3.86 
I ^ 4 0 . T 3.73 
I « _ / / £ ‘ 膽 - ' _ 隱 , 令 1 I I 3.5- | | H H B 
|_/A StL^  1 ^ ^ 1 .3.0：! ？ B B WB 
I ” 1/iSlI * \ ^ MFrrhX)UMIN 鲁 \rzsv * I-MKTFX)RMiN | J 2.5 • m m p m H ^ ^ ^ ^ H 
I z/ St, • I ^  MCTKORMIN • SU • I - METFORMIN . J 2.0 - ^^^ | ^^^ | ^^^ | • • • 
SlArt of « 1.0 - ^^ H^ ^^ B^ ^^ H^ 2 ^^^B ^^^^ ^^^B 
I 0-5 - 0.05 ^ H -0.24 ^ H -0.09 W M 
TVeatments ^ � • � ： - ^ ^ - " - . i . " ~ ^ " ^ L _ » 
• 27 patients who were previously on metformin stopped the metformin -0.5 J 
t r e a t m e n t ( ' S T O P P E D METFORMIN') NO STOPPED NO STOPPED NO STOPPED METFORMIN 
• 24 patients were not metformin treatment, served as control group Fast Post-Breakfast Pre-Dlnner 
('N0 METFORMIN') 
• No actjustment ofinsulin or other OHA 
RFSULTS W The group with no metformin treatment required a significantly 
^ larger dose ofinsulin to maintain glycemic control 
Demographics 
“ Ali NO STOPPED 251 23.0 
； Patients METFORMIN METFORMIN 
n 5r 24 27 妄 | | ^ H 
Age (years) 59t1Q.5 61t9.5 62±8.8 . ‘ • ^ ^ ^ H 
Duration ofdiafaetes(years) 12t5.Q 11i5.5 13.5t4.1 ^ ^°； ^ ^ ^ B 
：DurationofOHAtherapy<years| 11t4.8 10t4.8 13.2±4.2 | ^ ^ ^ H 
Duration of combination therapy (years) 1.2t l .3 0.9t1.1 1.4t1.3 ~ .S ^ ^ ^ H 
*/ patiem withdrawn from the earlierstudY, hence only51 patients were includedin the analysis. | 15 ‘ ^ ^ ^ ^ | 13.7 
INO METFORMIN: 1/2 SU +1. SU f /; STOPPED METFORMIN: J/2 SU * l-METFORMIN. SU * l-METFORMIN| | ^ ^ ^ ^ ^ 1 ^ ^ 
(a) The group stopping metformin showed a statustically significant ^ ^^^^H ^^^^H 
increase infasting plasma glucose(tTG) level ^^^^H ^^^^^| 
10 J — ^ —Hi i^H 
‘》.「, n 0 en NO ST()I'l'F:i) 
- ‘ , 0 : ^j METFORMIN MKTFORMIN 
• • 
^ ^ B 
2.r. ^ ^ H C O N C L U S I O N S 
^ ^ 1 
h l.r) - ^ ^ ^ ^ 1 • Stopping metformin in patients previously treated with it 
I 1.0� ^ ^ ^ ^ 1 affected their glycemic control, indicated by the statistically 
<i: o.r>: ^^^^H significant increase in fasting plasma glucose, HbA,r and 
M 00 -0』1 I ^ H H _ blood glucose level 
目 . ^ 
6 ^' "^' ‘ • A larger dose of insulin was required to maintain glycomic 
• ' " — STOt'l'FI) control in patients not on met formin treatment lh<ui l,hosc 
MKTFOI<MlN MCTFOItMIN pat ients with metformin treatment 
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INTRODUCTION (a) The change in HbA,, from baseline was comparable between the 
Rccenl evidence suggests that in NIDDM patients with secondary drug failure, full SU treatment and the halved-SU treatment groups 
insulin-oral hypoglycemic agenLs (OHAs) combination therapy may achieve 
similar glycemic control at a lower insulin dose and with less weight gain ^^‘： 
compared to insulin therapy alone. The minimum effective dose of "" 
sulphonylurea and the long term efficacy of combination ther^y, however, io*i 
remain unanswered. In the present study, we evaluate the effects of halving Z gJ 
sulphonylurea dosage in Chinese NIDDM patients on combination therapy. < j^ ‘ � “ ‘‘ 
7r 
OBJECTIVE 6"i 
• To evaluate the metabolic and safety effect of reduction of sulphonylurea ® —i 1 r^— 
• wcck 0 wcc^k 丨2 wi*t*k 
dosage to half in patients using maximum sulphonylurea with or without fv i) (V3: baseline) (v 4) 
metformin in combination with insulin 一 Grp A — - Grp B 
STUDY DESIGN (b) No significant difference was observed in the change offasting 
Patients plasma glucose levelfrom baseline between tkefull-SU group and the 
.Chinese NIDDM patiente halved-SUgroup 
• Age 20 years or above ie 
• Diabetes with a duration for at least 2 years i5-
• Confirmed OHA failure 13- r T 
？丨?： 
TVpe of TVial | '9- ____«_«_^—_ -
• A randomised, open and parallel study J. 7I “ “ 
• A 2-phase trial, only phase 1 will be presented here ^ 2^ 
• Run-inperiodofl2weeksinwhichpatientswerestabilisedon combined 3I 
therapy | ] 
• TVeatinent period of 24 wceks (tJ»e first 4 weeks without change of insulin °^ 1 r 1 
dosage and the last 20 weeks with insulin reacUustment) ^ ^ \ ° (vaTb^eUne) 7 ¾ 
一 Grp A - - Grp B 
lVeatments 
• Full dose ofsuIphonylurea (SU) + insulin (I) 
• Halved dose ofsuIphonylurea (SU) + insulin (I) (c) Neithergroup dijfered in their insulin requirement to achieve similar 
(In each group, half of the patients were also treated with metformin (M)� glycaemic control to baseline 
i/2sii.i, , , GrpA GrpB p-value 
1 1 |GrpB 
Insulin dose (U/day) 
Sl' 4 I 
H / ^ V 1 , + I + M ! 丨 丨 二 Baselinevisit: 1316.1 17土7.2 0.06 
\ ^ End oftreatmentvisi l : 15±8.1 21 土9.7 — 
SU • ！ + M^Ss^SU + I + M, 
备 ‘ L ^ [ ； ； ； GrpA lncrementin dose 2.0i3.3 3.6 i4.8 0,21 
Swoeks 8 wpcks 8 weeks 8weeks 8weeks ^ 
Data are given as mean 土 SD. p < 0.05forbetween group comparisons 
Fixing Phaw 1 IiMilhi Fixing End of ln*ulin diwe rftndomi.Hation retitration InNulin done Phute 1 
CONCLUSIONS 
RESULTS 
• There was no statistically significant differences in efficacy of full 
Demographics sulphonylurea treatment compared to halved sulphonylurea treatment 
. 1 Halved dose ofsuIphonylurea was as equivalence as full dose of 
A"Pa"ents GrpA GrpB sulphonylurea in maintaining glycemic control 
_n 5T 27 25 
Age (years| 5g + iQ7 51 ±95 57 + ¾] 7 “ • The insulin dosage required was comparable between the full 
Durationofdiabetes(years) l2t4.9 Mts's i ^ ^ T " sulphonylurea and halved sulphonylurea groups 
Duration of OHA therapy (years) 11±4.7 13±5.2 10i3.7 • Tlie frequency of hypoglycemia was comparable bet ween the 
Durationofcombinationtherapy(years) u I u u I u 1 .1 i1 .2 ^““ su lphonylurea and halved su lphonylurea Kroups 
——-~— (data not shown) 
'f2patients withdrawn from the study, hence onfy52palients were includedin the analysis. (GrpA 
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